ALZHEIMERS DISEASE RESEARCH FOUNDATION: Form 990, tax year 2024
View the entire original 990 at ProPublica ↗
- Organization
- ALZHEIMERS DISEASE RESEARCH FOUNDATION (EIN 52-2396428)
- Tax period
- 2024-01-01 to 2024-12-31
- Filed
- 2025-05-08
- IRS object ID
- 202531289349302248
- Schema version
- 2024v5.1
- Source
- Download XML · Original 990 at ProPublica
Every field in the e-filed return. Faint text is the IRS element name, for citing.
- Return header
- Form 990
- Schedule A
- Schedule B
- Schedule C
- Schedule D
- Schedule F
- Schedule G
- Schedule I
- Schedule J
- Schedule L
- Schedule M
- Schedule O
Return header ReturnHeader
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return | 2025-05-08T13:48:41-05:00 | ReturnTs |
| Tax Period End | 2024-12-31 | TaxPeriodEndDt |
Preparer Firm PreparerFirmGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Firm EIN | 050409384 | PreparerFirmEIN |
Preparer Firm Name PreparerFirmName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | KAHN LITWIN RENZA & CO LTD | BusinessNameLine1Txt |
Preparer US Address PreparerUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 951 NORTH MAIN STREET | AddressLine1Txt |
| City | PROVIDENCE | CityNm |
| State Abbreviation | RI | StateAbbreviationCd |
| ZIP | 02904 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return Type | 990 | ReturnTypeCd |
| Tax Period Begin | 2024-01-01 | TaxPeriodBeginDt |
Filer Filer
| Field | Value | IRS element (for citing) |
|---|---|---|
| EIN | 522396428 | EIN |
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | ALZHEIMER'S DISEASE RESEARCH FOUNDATION | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Control | ALZH | BusinessNameControlTxt |
| Phone | 7812373800 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 34 WASHINGTON ST 230 | AddressLine1Txt |
| City | WELLESLEY HILLS | CityNm |
| State Abbreviation | MA | StateAbbreviationCd |
| ZIP | 02481 | ZIPCd |
Business Officer BusinessOfficerGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person | MARGARET E SMITH | PersonNm |
| Person Title | CEO | PersonTitleTxt |
| Phone | 7812373800 | PhoneNum |
| Signature | 2025-05-08 | SignatureDt |
| Discuss With Paid Preparer | Yes (1) | DiscussWithPaidPreparerInd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| IRS Responsible Prty Info Curr | 0 | IRSResponsiblePrtyInfoCurrInd |
Preparer Person PreparerPersonGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Person | SANDY ROSS | PreparerPersonNm |
| PTIN | P01399337 | PTIN |
| Phone | 4012742001 | PhoneNum |
| Preparation | 2025-05-05 | PreparationDt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Tax | 2024 | TaxYr |
| Build TS | 2025-03-06 01:10:19Z | BuildTS |
Form 990 IRS990
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Change | Yes (X) | AddressChangeInd |
Doing Business As Name DoingBusinessAsName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | CURE ALZHEIMER'S FUND | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Principal Officer | MARGARET E SMITH | PrincipalOfficerNm |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 34 WASHINGTON ST 230 | AddressLine1Txt |
| City | WELLESLEY HILLS | CityNm |
| State Abbreviation | MA | StateAbbreviationCd |
| ZIP | 02481 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Gross Receipts | $37,825,374 | GrossReceiptsAmt |
| Group Return For Affiliates | 0 | GroupReturnForAffiliatesInd |
| Organization501c3 | Yes (X) | Organization501c3Ind |
| Website Address | HTTP://CUREALZ.ORG/ | WebsiteAddressTxt |
| Type Of Organization Corp | Yes (X) | TypeOfOrganizationCorpInd |
| Formation | 2004 | FormationYr |
| Legal Domicile State | PA | LegalDomicileStateCd |
| Activity Or Mission | TO FUND RESEARCH WITH THE HIGHEST PROBABILITY OF PREVENTING, SLOWING OR REVERSING ALZHEIMER'S DISEASE. | ActivityOrMissionDesc |
| Voting Members Governing Body | 9 | VotingMembersGoverningBodyCnt |
| Voting Members Independent | 8 | VotingMembersIndependentCnt |
| Total Employee | 33 | TotalEmployeeCnt |
| Total Volunteers | 85 | TotalVolunteersCnt |
| Total Gross UBI | $0 | TotalGrossUBIAmt |
| Net Unrelated Bus Txbl Incm | $0 | NetUnrelatedBusTxblIncmAmt |
| PY Contributions Grants | $36,697,205 | PYContributionsGrantsAmt |
| CY Contributions Grants | $30,788,755 | CYContributionsGrantsAmt |
| PY Program Service Revenue | $0 | PYProgramServiceRevenueAmt |
| CY Program Service Revenue | $0 | CYProgramServiceRevenueAmt |
| PY Investment Income | $1,042,285 | PYInvestmentIncomeAmt |
| CY Investment Income | $964,653 | CYInvestmentIncomeAmt |
| PY Other Revenue | -$14,283 | PYOtherRevenueAmt |
| CY Other Revenue | $2,269 | CYOtherRevenueAmt |
| PY Total Revenue | $37,725,207 | PYTotalRevenueAmt |
| CY Total Revenue | $31,755,677 | CYTotalRevenueAmt |
| PY Grants And Similar Paid | $26,431,117 | PYGrantsAndSimilarPaidAmt |
| CY Grants And Similar Paid | $28,828,950 | CYGrantsAndSimilarPaidAmt |
| PY Benefits Paid To Members | $0 | PYBenefitsPaidToMembersAmt |
| CY Benefits Paid To Members | $0 | CYBenefitsPaidToMembersAmt |
| PY Salaries Comp Emp Bnft Paid | $4,878,104 | PYSalariesCompEmpBnftPaidAmt |
| CY Salaries Comp Emp Bnft Paid | $5,244,116 | CYSalariesCompEmpBnftPaidAmt |
| PY Total Prof Fndrsng Expns | $0 | PYTotalProfFndrsngExpnsAmt |
| CY Total Prof Fndrsng Expns | $0 | CYTotalProfFndrsngExpnsAmt |
| CY Total Fundraising Expense | $2,002,303 | CYTotalFundraisingExpenseAmt |
| PY Other Expenses | $3,324,327 | PYOtherExpensesAmt |
| CY Other Expenses | $2,926,002 | CYOtherExpensesAmt |
| PY Total Expenses | $34,633,548 | PYTotalExpensesAmt |
| CY Total Expenses | $36,999,068 | CYTotalExpensesAmt |
| PY Revenues Less Expenses | $3,091,659 | PYRevenuesLessExpensesAmt |
| CY Revenues Less Expenses | -$5,243,391 | CYRevenuesLessExpensesAmt |
| Total Assets BOY | $33,488,279 | TotalAssetsBOYAmt |
| Total Assets EOY | $28,586,231 | TotalAssetsEOYAmt |
| Total Liabilities BOY | $1,727,324 | TotalLiabilitiesBOYAmt |
| Total Liabilities EOY | $1,722,043 | TotalLiabilitiesEOYAmt |
| Net Assets Or Fund Balances BOY | $31,760,955 | NetAssetsOrFundBalancesBOYAmt |
| Net Assets Or Fund Balances EOY | $26,864,188 | NetAssetsOrFundBalancesEOYAmt |
| Mission | TO FUND RESEARCH WITH THE HIGHEST PROBABILITY OF PREVENTING, SLOWING OR REVERSING ALZHEIMER'S DISEASE. ALL OVERHEAD EXPENSES ARE PAID BY THE BOARD OF DIRECTORS, TRUSTEES AND CORE GROUP OF SELECT DONORS, ALLOWING 100% OF GENERAL DONATIONS TO FUND OUR RESEARCH PROGRAMS. | MissionDesc |
| Significant New Program Srvc | 0 | SignificantNewProgramSrvcInd |
| Significant Change | 0 | SignificantChangeInd |
| Expense | $30,000,392 | ExpenseAmt |
| Grant | $28,828,950 | GrantAmt |
| Desc | IN 2024, CURE ALZHEIMER'S FUND SUPPORTED 120 RESEARCH PROJECTS AT 66 LEADING RESEARCH INSTITUTIONS, FOR RESEARCH OUTPUT OF $30 MILLION. MANY PROJECTS PURSUED A DEEPER UNDERSTANDING OF THE MECHANISMS OF ACTION OF THE GENES AND VARIANTS WITH THE BIGGEST IMPACT ON RISK AND TIMING OF ALZHEIMER'S DISEASE. OTHER PROJECTS PURSUED NOVEL THEORIES AND TOOLS TO ASSESS POTENTIAL AVENUES FOR PREVENTION AND TREATMENT, IN PARTICULAR REGARDING THE ROLE OF NEUROINFLAMMATION, THE GUT MICROBIOME, AND THE IMMUNE SYSTEM IN HEALTHY BRAIN FUNCTION. ADDITIONAL EXPENSES INCLUDE HUSBANDRY OF TRANSGENIC ANIMAL MODELS BY A CONTRACT RESEARCH ORGANIZATION; THE DIRECT SUPPORT OF FACILITATING GRANTS AND THE AWARD PROCESS; AND COSTS ASSOCIATED WITH ASSESSING RESEARCH PROPOSALS AND DETERMINING FUNDING PRIORITIES. | Desc |
Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $3,783,862 | ExpenseAmt |
| Desc | CREATING AWARENESS TOOK THE FORM OF MAILINGS, OUTREACH, WEBINARS, AND SUPPORT OF THIRD PARTY EVENTS DESIGNED TO RAISE AWARENESS ABOUT THE NEED OF MORE RESEARCH INTO THE ORIGINS AND PROGRESSION OF ALZHEIMER'S DISEASE. | Desc |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Program Service Expenses | $33,784,254 | TotalProgramServiceExpensesAmt |
| Described In Section501c3 | Yes (1) | DescribedInSection501c3Ind |
| Schedule B Required | Yes (1) | ScheduleBRequiredInd |
| Political Campaign Acty | 0 | PoliticalCampaignActyInd |
| Lobbying Activities | Yes (1) | LobbyingActivitiesInd |
| Subject To Proxy Tax | 0 | SubjectToProxyTaxInd |
| Donor Advised Fund | 0 | DonorAdvisedFundInd |
| Conservation Easements | 0 | ConservationEasementsInd |
| Collections Of Art | 0 | CollectionsOfArtInd |
| Credit Counseling | 0 | CreditCounselingInd |
| Donor Rstr Or Quasi Endowments | 0 | DonorRstrOrQuasiEndowmentsInd |
| Report Land Building Equipment | Yes (1) | ReportLandBuildingEquipmentInd |
| Report Investments Other Sec | 0 | ReportInvestmentsOtherSecInd |
| Report Program Related Invst | 0 | ReportProgramRelatedInvstInd |
| Report Other Assets | 0 | ReportOtherAssetsInd |
| Report Other Liabilities | Yes (1) | ReportOtherLiabilitiesInd |
| Include FIN48 Footnote | Yes (1) | IncludeFIN48FootnoteInd |
| Independent Audit Fincl Stmt | Yes (1) | IndependentAuditFinclStmtInd |
| Consolidated Audit Fincl Stmt | 0 | ConsolidatedAuditFinclStmtInd |
| School Operating | 0 | SchoolOperatingInd |
| Foreign Office | 0 | ForeignOfficeInd |
| Foreign Activities | Yes (1) | ForeignActivitiesInd |
| More Than5000 K To Org | Yes (1) | MoreThan5000KToOrgInd |
| More Than5000 K To Individuals | 0 | MoreThan5000KToIndividualsInd |
| Professional Fundraising | 0 | ProfessionalFundraisingInd |
| Fundraising Activities | Yes (1) | FundraisingActivitiesInd |
| Gaming Activities | 0 | GamingActivitiesInd |
| Operate Hospital | 0 | OperateHospitalInd |
| Grants To Organizations | Yes (1) | GrantsToOrganizationsInd |
| Grants To Individuals | 0 | GrantsToIndividualsInd |
| Schedule J Required | Yes (1) | ScheduleJRequiredInd |
| Tax Exempt Bonds | 0 | TaxExemptBondsInd |
| Engaged In Excess Benefit Trans | 0 | EngagedInExcessBenefitTransInd |
| PY Excess Benefit Trans | 0 | PYExcessBenefitTransInd |
| Loan Outstanding | 0 | LoanOutstandingInd |
| Grant To Related Person | 0 | GrantToRelatedPersonInd |
| Business Rln With Org Mem | 0 | BusinessRlnWithOrgMemInd |
| Business Rln With Fam Mem | 0 | BusinessRlnWithFamMemInd |
| Business Rln With35 Ctrl Ent | Yes (1) | BusinessRlnWith35CtrlEntInd |
| Deductible Non Cash Contri | Yes (1) | DeductibleNonCashContriInd |
| Deductible Art Contribution | 0 | DeductibleArtContributionInd |
| Terminate Operations | 0 | TerminateOperationsInd |
| Partial Liquidation | 0 | PartialLiquidationInd |
| Disregarded Entity | 0 | DisregardedEntityInd |
| Related Entity | 0 | RelatedEntityInd |
| Related Organization Ctrl Ent | 0 | RelatedOrganizationCtrlEntInd |
| Trnsfr Exmpt Non Chrtbl Rltd Org | 0 | TrnsfrExmptNonChrtblRltdOrgInd |
| Activities Conducted Prtshp | 0 | ActivitiesConductedPrtshpInd |
| Schedule O Required | Yes (1) | ScheduleORequiredInd |
| IRP Document | 36 | IRPDocumentCnt |
| IRP Document W2 G | 0 | IRPDocumentW2GCnt |
| Employee | 33 | EmployeeCnt |
| Employment Tax Returns Filed | Yes (1) | EmploymentTaxReturnsFiledInd |
| Unrelated Bus Incm Over Limit | 0 | UnrelatedBusIncmOverLimitInd |
| Foreign Financial Account | 0 | ForeignFinancialAccountInd |
| Prohibited Tax Shelter Trans | 0 | ProhibitedTaxShelterTransInd |
| Taxable Party Notification | 0 | TaxablePartyNotificationInd |
| Nondeductible Contributions | 0 | NondeductibleContributionsInd |
| Quid Pro Quo Contributions | Yes (1) | QuidProQuoContributionsInd |
| Quid Pro Quo Contri Discl | Yes (1) | QuidProQuoContriDisclInd |
| Form8282 Property Disposed Of | Yes (1) | Form8282PropertyDisposedOfInd |
| Form8282 Filed | 1 | Form8282FiledCnt |
| Rcv Fnds To Pay Prsnl Bnft Cntrct | 0 | RcvFndsToPayPrsnlBnftCntrctInd |
| Pay Premiums Prsnl Bnft Cntrct | 0 | PayPremiumsPrsnlBnftCntrctInd |
| Indoor Tanning Services | 0 | IndoorTanningServicesInd |
| Subj To Tax Rmnrtn Ex Prcht Pymt | 0 | SubjToTaxRmnrtnExPrchtPymtInd |
| Subject To Excs Tax Net Invst Inc | 0 | SubjectToExcsTaxNetInvstIncInd |
| Info In Schedule O Part VI | Yes (X) | InfoInScheduleOPartVIInd |
| Governing Body Voting Members | 9 | GoverningBodyVotingMembersCnt |
| Independent Voting Member | 8 | IndependentVotingMemberCnt |
| Family Or Business Rln | 0 | FamilyOrBusinessRlnInd |
| Delegation Of Mgmt Duties | 0 | DelegationOfMgmtDutiesInd |
| Change To Org Documents | Yes (1) | ChangeToOrgDocumentsInd |
| Material Diversion Or Misuse | 0 | MaterialDiversionOrMisuseInd |
| Members Or Stockholders | 0 | MembersOrStockholdersInd |
| Election Of Board Members | 0 | ElectionOfBoardMembersInd |
| Decisions Subject To Approva | 0 | DecisionsSubjectToApprovaInd |
| Minutes Of Governing Body | Yes (1) | MinutesOfGoverningBodyInd |
| Minutes Of Committees | Yes (1) | MinutesOfCommitteesInd |
| Officer Mailing Address | 0 | OfficerMailingAddressInd |
| Local Chapters | 0 | LocalChaptersInd |
| Form990 Provided To Gvrn Body | Yes (1) | Form990ProvidedToGvrnBodyInd |
| Conflict Of Interest Policy | Yes (1) | ConflictOfInterestPolicyInd |
| Annual Disclosure Covered Prsn | Yes (1) | AnnualDisclosureCoveredPrsnInd |
| Regular Monitoring Enfrc | Yes (1) | RegularMonitoringEnfrcInd |
| Whistleblower Policy | Yes (1) | WhistleblowerPolicyInd |
| Document Retention Policy | Yes (1) | DocumentRetentionPolicyInd |
| Compensation Process CEO | Yes (1) | CompensationProcessCEOInd |
| Compensation Process Other | Yes (1) | CompensationProcessOtherInd |
| Investment In Joint Venture | 0 | InvestmentInJointVentureInd |
| States Where Copy Of Return Is Fld | MA | StatesWhereCopyOfReturnIsFldCd |
| Own Website | Yes (X) | OwnWebsiteInd |
| Other Website | Yes (X) | OtherWebsiteInd |
| Upon Request | Yes (X) | UponRequestInd |
Books In Care Of Detail BooksInCareOfDetail
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | MARGARET E SMITH | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Phone | 7812373800 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 34 WASHINGTON STREET STE 230 | AddressLine1Txt |
| City | WELLESLEY HILLS | CityNm |
| State Abbreviation | MA | StateAbbreviationCd |
| ZIP | 02481 | ZIPCd |
Form990 Part VII Section A Form990PartVIISectionAGrp (20 entries)
| TitleTitleTxt | Average Hours Per WeekAverageHoursPerWeekRt | Individual Trustee Or DirectorIndividualTrusteeOrDirectorInd | OfficerOfficerInd | Reportable Comp From OrgReportableCompFromOrgAmt | Reportable Comp From Rltd OrgReportableCompFromRltdOrgAmt | Other CompensationOtherCompensationAmt | Key EmployeeKeyEmployeeInd | Highest Compensated EmployeeHighestCompensatedEmployeeInd |
|---|---|---|---|---|---|---|---|---|
| MARGARET E SMITH | ||||||||
| CEO | 40.00 | Yes (X) | Yes (X) | $426,320 | $0 | $29,113 | ||
| HENRY MCCANCE | ||||||||
| CHAIR | 5.00 | Yes (X) | Yes (X) | $0 | $0 | $0 | ||
| PHYLLIS RAPPAPORT | ||||||||
| TREASURER | 5.00 | Yes (X) | Yes (X) | $0 | $0 | $0 | ||
| TIMOTHY ARMOUR | ||||||||
| DIRECTOR | 3.00 | Yes (X) | $0 | $0 | $0 | |||
| RICHARD BIRNBAUM | ||||||||
| DIRECTOR | 4.00 | Yes (X) | $0 | $0 | $0 | |||
| MARK FAGGIANO | ||||||||
| DIRECTOR (FROM 10/24) | 3.00 | Yes (X) | $0 | $0 | $0 | |||
| MARY GREENHILL CAGLIERO | ||||||||
| DIRECTOR (FROM 10/24) | 3.00 | Yes (X) | $0 | $0 | $0 | |||
| ROBERT GREENHILL | ||||||||
| DIRECTOR (TO 10/24) | 3.00 | Yes (X) | $0 | $0 | $0 | |||
| KUMAR MAHADEVA | ||||||||
| DIRECTOR (FROM 12/24) | 3.00 | Yes (X) | $0 | $0 | $0 | |||
| JACQUELINE MORBY | ||||||||
| DIRECTOR | 4.00 | Yes (X) | $0 | $0 | $0 | |||
| JOSEPHINE ANTONELLIS | ||||||||
| CFO | 30.00 | Yes (X) | $200,226 | $0 | $7,215 | |||
| LAUREL LYLE | ||||||||
| SECRETARY & VP BOARD RELATIONS & DEV OPS | 30.00 | Yes (X) | $121,094 | $0 | $4,232 | |||
| KATHARINE HERMAN | ||||||||
| EVP DEVELOPMENT | 40.00 | $418,581 | $0 | $30,236 | Yes (X) | |||
| JULIE HARRIS | ||||||||
| EVP RESEARCH MGMT (TO 12/24) | 40.00 | $296,359 | $0 | $9,851 | Yes (X) | |||
| BARBARA CHAMBERS | ||||||||
| EVP MARKETING & COMM. | 40.00 | $267,548 | $0 | $23,094 | Yes (X) | |||
| LISA RAND | ||||||||
| VP MARKETING & COMM. | 40.00 | $199,320 | $0 | $18,515 | Yes (X) | |||
| DANIEL HARPER | ||||||||
| VP DEVELOPMENT | 40.00 | $195,493 | $0 | $12,700 | Yes (X) | |||
| JOHN SLATTERY | ||||||||
| SVP, PHILANTHROPIC PARTNERSHIPS | 40.00 | $198,792 | $0 | $6,983 | Yes (X) | |||
| MAHUA DASGUPTA | ||||||||
| SR. PHILANTROPIC ADVISOR | 40.00 | $178,255 | $0 | $25,399 | Yes (X) | |||
| THIDAPHORN SENGSAVANH | ||||||||
| DIRECTOR OF DEVELOPMENT OPS | 40.00 | $154,055 | $0 | $24,241 | Yes (X) | |||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Reportable Comp From Org | $2,656,043 | TotalReportableCompFromOrgAmt |
| Tot Reportable Comp Rltd Org | $0 | TotReportableCompRltdOrgAmt |
| Total Other Compensation | $191,579 | TotalOtherCompensationAmt |
| Indiv Rcvd Greater Than100 K | 16 | IndivRcvdGreaterThan100KCnt |
| Former Ofcr Employees Listed | 0 | FormerOfcrEmployeesListedInd |
| Total Comp Greater Than150 K | Yes (1) | TotalCompGreaterThan150KInd |
| Compensation From Other Srcs | 0 | CompensationFromOtherSrcsInd |
Contractor Compensation ContractorCompensationGrp
Contractor Name ContractorName
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | PROPER VILLAINS LLC | BusinessNameLine1Txt |
Contractor Address ContractorAddress
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 855 BOYLSTON STREET 10TH FLOOR | AddressLine1Txt |
| City | BOSTON | CityNm |
| State Abbreviation | MA | StateAbbreviationCd |
| ZIP | 02116 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Services | CREATIVE AND PRODUCTION SERVICES | ServicesDesc |
| Compensation | $250,941 | CompensationAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Cntrct Rcvd Greater Than100 K | 1 | CntrctRcvdGreaterThan100KCnt |
| Fundraising | $236,522 | FundraisingAmt |
| All Other Contributions | $30,552,233 | AllOtherContributionsAmt |
| Noncash Contributions | $5,918,750 | NoncashContributionsAmt |
| Total Contributions | $30,788,755 | TotalContributionsAmt |
Investment Income InvestmentIncomeGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $997,714 | TotalRevenueColumnAmt |
| Exclusion | $997,714 | ExclusionAmt |
Gross Amount Sales Assets GrossAmountSalesAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | $5,684,629 | SecuritiesAmt |
| Other | $250,276 | OtherAmt |
Less Cost Oth Basis Sales Expnss LessCostOthBasisSalesExpnssGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | $5,695,860 | SecuritiesAmt |
| Other | $272,106 | OtherAmt |
Gain Or Loss GainOrLossGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | -$11,231 | SecuritiesAmt |
| Other | -$21,830 | OtherAmt |
Net Gain Or Loss Investments NetGainOrLossInvestmentsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | -$33,061 | TotalRevenueColumnAmt |
| Exclusion | -$33,061 | ExclusionAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Fundraising Gross Income | $104,000 | FundraisingGrossIncomeAmt |
| Contri Rpt Fundraising Event | $236,522 | ContriRptFundraisingEventAmt |
| Fundraising Direct Expenses | $101,731 | FundraisingDirectExpensesAmt |
Net Incm From Fundraising Evt NetIncmFromFundraisingEvtGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $2,269 | TotalRevenueColumnAmt |
| Exclusion | $2,269 | ExclusionAmt |
Total Revenue TotalRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $31,755,677 | TotalRevenueColumnAmt |
| Related Or Exempt Func Income | $0 | RelatedOrExemptFuncIncomeAmt |
| Unrelated Business Revenue | $0 | UnrelatedBusinessRevenueAmt |
| Exclusion | $966,922 | ExclusionAmt |
Grants To Domestic Orgs GrantsToDomesticOrgsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $24,417,387 | TotalAmt |
| Program Services | $24,417,387 | ProgramServicesAmt |
Foreign Grants ForeignGrantsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $4,411,563 | TotalAmt |
| Program Services | $4,411,563 | ProgramServicesAmt |
Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,833,869 | TotalAmt |
| Program Services | $1,068,754 | ProgramServicesAmt |
| Management And General | $379,849 | ManagementAndGeneralAmt |
| Fundraising | $385,266 | FundraisingAmt |
Other Salaries And Wages OtherSalariesAndWagesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $2,771,451 | TotalAmt |
| Program Services | $1,588,294 | ProgramServicesAmt |
| Management And General | $400,877 | ManagementAndGeneralAmt |
| Fundraising | $782,280 | FundraisingAmt |
Pension Plan Contributions PensionPlanContributionsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $77,621 | TotalAmt |
| Program Services | $44,410 | ProgramServicesAmt |
| Management And General | $11,100 | ManagementAndGeneralAmt |
| Fundraising | $22,111 | FundraisingAmt |
Other Employee Benefits OtherEmployeeBenefitsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $232,224 | TotalAmt |
| Program Services | $131,735 | ProgramServicesAmt |
| Management And General | $41,248 | ManagementAndGeneralAmt |
| Fundraising | $59,241 | FundraisingAmt |
Payroll Taxes PayrollTaxesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $328,951 | TotalAmt |
| Program Services | $195,354 | ProgramServicesAmt |
| Management And General | $53,661 | ManagementAndGeneralAmt |
| Fundraising | $79,936 | FundraisingAmt |
Fees For Services Legal FeesForServicesLegalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $26,187 | TotalAmt |
| Program Services | $8,312 | ProgramServicesAmt |
| Management And General | $3,225 | ManagementAndGeneralAmt |
| Fundraising | $14,650 | FundraisingAmt |
Fees For Services Accounting FeesForServicesAccountingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $39,123 | TotalAmt |
| Management And General | $39,123 | ManagementAndGeneralAmt |
Fees For Services Lobbying FeesForServicesLobbyingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $81,000 | TotalAmt |
| Program Services | $81,000 | ProgramServicesAmt |
Fees For Srvc Invst Mgmnt Fees FeesForSrvcInvstMgmntFeesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $28,594 | TotalAmt |
| Management And General | $28,594 | ManagementAndGeneralAmt |
Fees For Services Other FeesForServicesOtherGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $394,657 | TotalAmt |
| Program Services | $189,599 | ProgramServicesAmt |
| Management And General | $43,291 | ManagementAndGeneralAmt |
| Fundraising | $161,767 | FundraisingAmt |
Advertising AdvertisingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $672,478 | TotalAmt |
| Program Services | $672,478 | ProgramServicesAmt |
Office Expenses OfficeExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $205,044 | TotalAmt |
| Program Services | $66,698 | ProgramServicesAmt |
| Management And General | $41,069 | ManagementAndGeneralAmt |
| Fundraising | $97,277 | FundraisingAmt |
Information Technology InformationTechnologyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $97,396 | TotalAmt |
| Program Services | $11,555 | ProgramServicesAmt |
| Management And General | $84,399 | ManagementAndGeneralAmt |
| Fundraising | $1,442 | FundraisingAmt |
Occupancy OccupancyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $203,490 | TotalAmt |
| Program Services | $116,214 | ProgramServicesAmt |
| Management And General | $35,011 | ManagementAndGeneralAmt |
| Fundraising | $52,265 | FundraisingAmt |
Travel TravelGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $138,200 | TotalAmt |
| Program Services | $51,088 | ProgramServicesAmt |
| Management And General | $3,723 | ManagementAndGeneralAmt |
| Fundraising | $83,389 | FundraisingAmt |
Conferences Meetings ConferencesMeetingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $423,373 | TotalAmt |
| Program Services | $338,690 | ProgramServicesAmt |
| Management And General | $21,790 | ManagementAndGeneralAmt |
| Fundraising | $62,893 | FundraisingAmt |
Depreciation Depletion DepreciationDepletionGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $724 | TotalAmt |
| Program Services | $183 | ProgramServicesAmt |
| Management And General | $123 | ManagementAndGeneralAmt |
| Fundraising | $418 | FundraisingAmt |
Insurance InsuranceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $26,363 | TotalAmt |
| Program Services | $4,756 | ProgramServicesAmt |
| Management And General | $19,517 | ManagementAndGeneralAmt |
| Fundraising | $2,090 | FundraisingAmt |
Other Expenses OtherExpensesGrp (3 entries)
| DescDesc | TotalTotalAmt | Program ServicesProgramServicesAmt | FundraisingFundraisingAmt | Management And GeneralManagementAndGeneralAmt |
|---|---|---|---|---|
| RESEARCH LAB EXPENSES | $352,275 | $352,275 | ||
| GIFT PROCESSING FEES | $176,286 | $176,286 | ||
| MISCELLANEOUS | $60,812 | $33,909 | $20,992 | $5,911 |
Total Functional Expenses TotalFunctionalExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $36,999,068 | TotalAmt |
| Program Services | $33,784,254 | ProgramServicesAmt |
| Management And General | $1,212,511 | ManagementAndGeneralAmt |
| Fundraising | $2,002,303 | FundraisingAmt |
Cash Non Interest Bearing CashNonInterestBearingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $1,219,384 | BOYAmt |
| EOY | $2,815,537 | EOYAmt |
Savings And Temp Cash Invst SavingsAndTempCashInvstGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $3,993,426 | BOYAmt |
| EOY | $322,954 | EOYAmt |
Pledges And Grants Receivable PledgesAndGrantsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $3,783,152 | BOYAmt |
| EOY | $1,707,733 | EOYAmt |
Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $239,429 | BOYAmt |
| EOY | $246,040 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Land Bldg Equip Cost Or Other Bss | $8,688 | LandBldgEquipCostOrOtherBssAmt |
| Land Bldg Equip Accum Deprec | $724 | LandBldgEquipAccumDeprecAmt |
Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $0 | BOYAmt |
| EOY | $7,964 | EOYAmt |
Investments Pub Traded Sec InvestmentsPubTradedSecGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $24,112,740 | BOYAmt |
| EOY | $23,255,145 | EOYAmt |
Other Assets Total OtherAssetsTotalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $140,148 | BOYAmt |
| EOY | $230,858 | EOYAmt |
Total Assets TotalAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $33,488,279 | BOYAmt |
| EOY | $28,586,231 | EOYAmt |
Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $316,299 | BOYAmt |
| EOY | $167,083 | EOYAmt |
Grants Payable GrantsPayableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $718,427 | BOYAmt |
| EOY | $600,901 | EOYAmt |
Other Liabilities OtherLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $692,598 | BOYAmt |
| EOY | $954,059 | EOYAmt |
Total Liabilities TotalLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $1,727,324 | BOYAmt |
| EOY | $1,722,043 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Organization Follows FASB117 | Yes (X) | OrganizationFollowsFASB117Ind |
No Donor Restriction Net Assets NoDonorRestrictionNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $27,791,118 | BOYAmt |
| EOY | $25,165,313 | EOYAmt |
Donor Restriction Net Assets DonorRestrictionNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $3,969,837 | BOYAmt |
| EOY | $1,698,875 | EOYAmt |
Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $31,760,955 | BOYAmt |
| EOY | $26,864,188 | EOYAmt |
Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $33,488,279 | BOYAmt |
| EOY | $28,586,231 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Reconcilation Revenue Expnss | -$5,243,391 | ReconcilationRevenueExpnssAmt |
| Net Unrlzd Gains Losses Invst | $346,624 | NetUnrlzdGainsLossesInvstAmt |
| Other Changes In Net Assets | $0 | OtherChangesInNetAssetsAmt |
| Method Of Accounting Accrual | Yes (X) | MethodOfAccountingAccrualInd |
| Accountant Compile Or Review | 0 | AccountantCompileOrReviewInd |
| FS Audited | Yes (1) | FSAuditedInd |
FS Audited Basis FSAuditedBasisGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Separate Basis Fincl Stmt | Yes (X) | SeparateBasisFinclStmtInd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Audit Committee | Yes (1) | AuditCommitteeInd |
| Federal Grant Audit Required | 0 | FederalGrantAuditRequiredInd |
Schedule A IRS990ScheduleA
| Field | Value | IRS element (for citing) |
|---|---|---|
| Public Organization170 | Yes (X) | PublicOrganization170Ind |
Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $22,874,388 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $26,547,838 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $32,354,655 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $36,697,205 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $30,788,755 | CurrentTaxYearAmt |
| Total | $149,262,841 | TotalAmt |
Total Calendar Year170 TotalCalendarYear170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $22,874,388 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $26,547,838 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $32,354,655 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $36,697,205 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $30,788,755 | CurrentTaxYearAmt |
| Total | $149,262,841 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Substantial Contributors Tot | $18,414,151 | SubstantialContributorsTotAmt |
| Public Support Total170 | $130,848,690 | PublicSupportTotal170Amt |
Gross Investment Income170 GrossInvestmentIncome170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $15,472 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $4,497 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $93,408 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $992,260 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $997,714 | CurrentTaxYearAmt |
| Total | $2,103,351 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Support | $151,366,192 | TotalSupportAmt |
| Gross Receipts Rltd Activities | $317,300 | GrossReceiptsRltdActivitiesAmt |
| Public Support CY170 | 0.86450 | PublicSupportCY170Pct |
| Public Support PY170 | 0.87500 | PublicSupportPY170Pct |
| Thirty Thr Pct Suprt Tests CY170 | Yes (X) | ThirtyThrPctSuprtTestsCY170Ind |
Schedule B IRS990ScheduleB
Contributor Information ContributorInformationGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Contributor | RESTRICTED | ContributorNum |
Contributor Business Name ContributorBusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | RESTRICTED | BusinessNameLine1 |
Contributor US Address ContributorUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | RESTRICTED | AddressLine1 |
| Address Line2 | RESTRICTED | AddressLine2 |
| City | RESTRICTED | City |
| State | RESTRICTED | State |
| ZIP Code | RESTRICTED | ZIPCode |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Contributions | RESTRICTED | TotalContributionsAmt |
Schedule C IRS990ScheduleC
| Field | Value | IRS element (for citing) |
|---|---|---|
| Volunteers | 0 | VolunteersInd |
| Paid Staff Or Management | 0 | PaidStaffOrManagementInd |
| Media Advertisements | 0 | MediaAdvertisementsInd |
| Mailings Members | 0 | MailingsMembersInd |
| Publications Or Broadcast | 0 | PublicationsOrBroadcastInd |
| Grants Other Organizations | 0 | GrantsOtherOrganizationsInd |
| Direct Contact Legislators | Yes (1) | DirectContactLegislatorsInd |
| Direct Contact Legislators | $81,000 | DirectContactLegislatorsAmt |
| Rallies Demonstrations | 0 | RalliesDemonstrationsInd |
| Other Activities | 0 | OtherActivitiesInd |
| Total Lobbying Expenditures | $81,000 | TotalLobbyingExpendituresAmt |
| Not Described Section501c3 | 0 | NotDescribedSection501c3Ind |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART II-B, LINE 1(G) | FormAndLineReferenceDesc |
| Explanation | A REGISTERED LOBBYIST CONTACTED VARIOUS CONGRESSIONAL LEGISLATORS FOR THE PURPOSE OF ENCOURAGING INCREASED FUNDING OF ALZHEIMER'S DISEASE RESEARCH BY THE FEDERAL GOVERNMENT. | ExplanationTxt |
Schedule D IRS990ScheduleD
Leasehold Improvements LeaseholdImprovementsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $8,688 | OtherCostOrOtherBasisAmt |
| Depreciation | $724 | DepreciationAmt |
| Book Value | $7,964 | BookValueAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Book Value Land Buildings | $7,964 | TotalBookValueLandBuildingsAmt |
Other Liabilities Org OtherLiabilitiesOrgGrp (2 entries)
| DescDesc | AmtAmt |
|---|---|
| ACCRUED PAYROLL AND RELATED | $730,551 |
| LEASE PAYABLE | $223,508 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Liability | $954,059 | TotalLiabilityAmt |
| Footnote Text | Yes (X) | FootnoteTextInd |
| Total Rev Etc Audited Fincl Stmt | $32,073,707 | TotalRevEtcAuditedFinclStmtAmt |
| Net Unrealized Gains Invst | $346,624 | NetUnrealizedGainsInvstAmt |
| Revenue Not Reported | $346,624 | RevenueNotReportedAmt |
| Revenue Subtotal | $31,727,083 | RevenueSubtotalAmt |
| Investment Expenses Not Incld | $28,594 | InvestmentExpensesNotIncldAmt |
| Revenue Not Reported Fincl Stmt | $28,594 | RevenueNotReportedFinclStmtAmt |
| Total Revenue Per Form990 | $31,755,677 | TotalRevenuePerForm990Amt |
| Tot Expns Etc Audited Fincl Stmt | $36,970,474 | TotExpnsEtcAuditedFinclStmtAmt |
| Expenses Not Reported | $0 | ExpensesNotReportedAmt |
| Expenses Subtotal | $36,970,474 | ExpensesSubtotalAmt |
| Investment Expenses Not Incld2 | $28,594 | InvestmentExpensesNotIncld2Amt |
| Expenses Not Rpt Fincl Stmt | $28,594 | ExpensesNotRptFinclStmtAmt |
| Total Expenses Per Form990 | $36,999,068 | TotalExpensesPerForm990Amt |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART X, LINE 2: | FormAndLineReferenceDesc |
| Explanation | THE ORGANIZATION IS EXEMPT FROM INCOME TAXES AS A PUBLIC CHARITY UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE. MANAGEMENT BELIEVES THAT THE ORGANIZATION OPERATES IN A MANNER CONSISTENT WITH ITS TAX-EXEMPT STATUS AT BOTH THE STATE AND FEDERAL LEVELS. THE ORGANIZATION ANNUALLY FILES IRS FORM 990 RETURNS OF ORGANIZATIONS EXEMPT FROM INCOME TAX, REPORTING VARIOUS INFORMATION THAT THE IRS USES TO MONITOR THE ACTIVITIES OF TAX-EXEMPT ENTITIES. THESE TAX RETURNS ARE SUBJECT TO REVIEW BY THE TAXING AUTHORITIES, GENERALLY FOR A PERIOD OF THREE YEARS AFTER THEY WERE FILED. THE ORGANIZATION CURRENTLY HAS NO TAX EXAMINATIONS IN PROGRESS. | ExplanationTxt |
Schedule F IRS990ScheduleF
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (1) | GrantRecordsMaintainedInd |
Account Activities Outside US AccountActivitiesOutsideUSGrp (4 entries)
| RegionRegionTxt | OfficesOfficesCnt | EmployeeEmployeeCnt | Type Of Activities ConductedTypeOfActivitiesConductedTxt | Specific Services ProvidedSpecificServicesProvidedTxt | Region Total ExpendituresRegionTotalExpendituresAmt |
|---|---|---|---|---|---|
| EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM | 0 | 0 | GRANTS AWARDED | ALZHEIMER'S DISEASE RESEARCH | $2,618,347 |
| MIDDLE EAST AND NORTH AFRICA - ALGERIA, BAHRAIN, DJIBOUTI, EGYPT, | 0 | 0 | GRANTS AWARDED | ALZHEIMER'S DISEASE RESEARCH | $330,913 |
| EAST ASIA AND THE PACIFIC - AUSTRALIA, BRUNEI, BURMA, CAMBODIA, | 0 | 0 | GRANTS AWARDED | ALZHEIMER'S DISEASE RESEARCH | $918,676 |
| NORTH AMERICA | 0 | 0 | GRANTS AWARDED | ALZHEIMER'S DISEASE RESEARCH | $543,627 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Subtotal Offices | 0 | SubtotalOfficesCnt |
| Subtotal Employees | 0 | SubtotalEmployeesCnt |
| Continuation Total Office | 0 | ContinuationTotalOfficeCnt |
| Continuation Total Employee | 0 | ContinuationTotalEmployeeCnt |
| Total Office | 0 | TotalOfficeCnt |
| Total Employee | 0 | TotalEmployeeCnt |
| Subtotal Spent | $4,411,563 | SubtotalSpentAmt |
| Continuation Spent | $0 | ContinuationSpentAmt |
| Total Spent | $4,411,563 | TotalSpentAmt |
Grants To Org Outside US GrantsToOrgOutsideUSGrp (26 entries)
| RegionRegionTxt | Purpose Of GrantPurposeOfGrantTxt | Cash GrantCashGrantAmt | Manner Of Cash DisbursementMannerOfCashDisbursementTxt | Non Cash AssistanceNonCashAssistanceAmt |
|---|---|---|---|---|
| BELGIUM | IDENTIFYING MEDIATORS OF TAU MEDIATED NEURONAL NECROPTOSIS USING AN INNOVATIVE IN VIVO CRISPR SCREEN | $230,000 | WIRE TRANSFER | $0 |
| BELGIUM | PRECLINICAL ANALYSIS OF SYNAPTOGYRIN-3 OLIGONUCLEOTIDES TO TARGET TAUOPATHY | $201,250 | WIRE TRANSFER | $0 |
| CANADA | ALZHEIMER'S DISEASE PET IMAGING OF NONFIBRILLAR AMYLOID BETA AGGREGATES USING AZAPEPTIDE (AZP) TRACER | $7,763 | WIRE TRANSFER | $0 |
| CANADA | COMBINED HORMONE THERAPY AS A NOVEL TREATMENT FOR ALZHEIMER'S DISEASE IN THE FACE OF A METABOLIC CHALLENGE: INFLUENCE OF SEX AND GENOTYPE | $201,250 | WIRE TRANSFER | $0 |
| CANADA | ALZHEIMER'S DISEASE PET IMAGING OF NONFIBRILLAR AMYLOID BETA AGGREGATES USING AZAPEPTIDE (AZP) TRACER | $47,115 | WIRE TRANSFER | $0 |
| CANADA | APOE CONSORTIUM: EFFECT OF CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY ON AMYLOID AND CEREBROVASCULAR PATHOLOGIES IN ANIMAL MODELS OF ALZHEIMER'S DISEASE - YEAR 2/2 | $287,500 | WIRE TRANSFER | $0 |
| GERMANY | SYSTEMATIC ASSESSMENT OF TANDEM REPEATS IN ALZHEIMER'S DISEASE (STAR-AD) | $181,500 | WIRE TRANSFER | $0 |
| GERMANY | SYSTEMATIC ASSESSMENT OF TANDEM REPEATS IN ALZHEIMER'S DISEASE (STAR-AD) - YEAR 1 OF 2 | $181,500 | WIRE TRANSFER | $0 |
| GERMANY | STRUCTURAL MIMICRY IN MICROBIAL AND ANTIMICROBIAL AMYLOIDS CONNECTED TO NEURODEGENERATIVE DISEASES | $200,400 | WIRE TRANSFER | $0 |
| HONG KONG | APOE IN CHOROID PLEXUS FUNCTION AND RELATED ALZHEIMER'S DISEASE PATHOGENESIS | $230,000 | WIRE TRANSFER | $0 |
| HONG KONG | APOE CONSORTIUM: APOE GENOTYPE-SPECIFIC EFFECTS OF HUMAN YOUNG PLASMA ON CEREBROVASCULATURE AND AD PATHOLOGY | $287,500 | WIRE TRANSFER | $0 |
| ISRAEL | ALZHEIMER'S DISEASE PET IMAGING OF NONFIBRILLAR AMYLOID BETA AGGREGATES USING AZAPEPTIDE (AZP) TRACER | $7,763 | WIRE TRANSFER | $0 |
| ISRAEL | A PROPOSAL TO EVALUATE THE EFFECT OF BCG VACCINATION ON ALZHEIMER'S DISEASE DEVELOPMENT | $121,900 | WIRE TRANSFER | $0 |
| ISRAEL | DECODING MICROBIAL PRODUCTS MODULATING ALZHEIMER'S DISEASE TOWARDS PRECISION POSTBIOTICS TREATMENT | $201,250 | WIRE TRANSFER | $0 |
| ITALY | EXTRACELLULAR ATP IS A KEY FACTOR IN PROMOTING ALZHEIMER'S DISEASE NEUROINFLAMMATION | $59,950 | WIRE TRANSFER | $0 |
| ITALY | EXTRACELLULAR ATP IS A KEY FACTOR IN PROMOTING ALZHEIMER'S DISEASE NEUROINFLAMMATION | $90,045 | WIRE TRANSFER | $0 |
| NEW ZEALAND | CHARACTERIZATION AND VALIDATION OF TWO RECENTLY CREATED SHEEP MODELS OF ALZHEIMER'S DISEASE IN PREPARATION FOR USE AS A PRECLINICAL PHARMACEUTICAL TESTING MODELS | $199,926 | WIRE TRANSFER | $0 |
| NORWAY | TURNING UP MITOPHAGY TO BLUNT ALZHEIMER TAU PATHOLOGIES | $200,675 | WIRE TRANSFER | $0 |
| NORWAY | ELUCIDATING MECHANISMS DRIVING THE COMPROMISED BALANCE BETWEEN MITOPHAGY AND CGAS-STING-INITIATED INFLAMMATION TOWARDS A TREATMENT FOR ALZHEIMER'S DISEASE | $90,000 | WIRE TRANSFER | $0 |
| SINGAPORE | MULTIDIMENSIONAL PROFILING OF TREM2-MUTATED OR APOE4-MUTATED MICROGLIA IN HUMAN BRAIN ORGANOIDS TO UNDERSTAND DYSREGULATED MICROGLIA NEURONAL CROSSTALK IN AD | $201,250 | WIRE TRANSFER | $0 |
| SWEDEN | ELUCIDATING MECHANISMS DRIVING THE COMPROMISED BALANCE BETWEEN MITOPHAGY AND CGAS-STING-INITIATED INFLAMMATION TOWARDS A TREATMENT FOR ALZHEIMER'S DISEASE | $108,490 | WIRE TRANSFER | $0 |
| SWEDEN | ALZHEIMER'S DISEASE TAU CONSORTIUM: DEEP MASS SPECTROMETRY PROFILING OF TAU AGGREGATES IN ALZHEIMER'S DISEASE AND OTHER TAUOPATHIES | $287,500 | WIRE TRANSFER | $0 |
| UNITED KINGDOM | ALZHEIMER'S DISEASE TAU CONSORTIUM: POST-TRANSLATIONAL MODIFICATIONS AND TAU ULTRASTRUCTURE; IMPACT OF ABETA ON TAU IN VIVO | $198,976 | WIRE TRANSFER | $0 |
| UNITED KINGDOM | CELLULAR VULNERABILITY TO PATHOLOGICAL TAU PROTEIN ACCUMULATION IN ALZHEIMER'S DISEASE | $219,880 | WIRE TRANSFER | $0 |
| UNITED KINGDOM | INVESTIGATING THE SERIAL PATHOLOGIES RELATED TO PLASMA BIOMARKERS IN NLFTAUM/H MICE; A NEW MOUSE MODEL FEATURING NEUROFIBRILLARY TANGLES AS A RESULT OF RISING AMYLOID WITHOUT MAPT MUTATIONS | $200,388 | WIRE TRANSFER | $0 |
| UNITED KINGDOM | ALZHEIMER'S DISEASE TAU CONSORTIUM: POST-TRANSLATIONAL MODIFICATIONS AND TAU ULTRASTRUCTURE; IMPACT OF ABETA ON TAU IN VIVO | $167,794 | WIRE TRANSFER | $0 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total501c3 Org | 26 | Total501c3OrgCnt |
| Total Other Org | 0 | TotalOtherOrgCnt |
| Transfer To Foreign Corp | 0 | TransferToForeignCorpInd |
| Interest In Foreign Trust | 0 | InterestInForeignTrustInd |
| Foreign Corp Ownership | 0 | ForeignCorpOwnershipInd |
| Passive Foreign Investmest Co | 0 | PassiveForeignInvestmestCoInd |
| Foreign Partnership | 0 | ForeignPartnershipInd |
| Boycott Countries | 0 | BoycottCountriesInd |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART I, LINE 2: | FormAndLineReferenceDesc |
| Explanation | THE RESEARCH LEADERSHIP GROUP REVIEWS EACH PROJECT FOR FIT WITH THE CUREALZ RESEARCH PORTFOLIO, SCIENTIFIC INTEGRITY, AND VALUE TO THE SEARCH FOR A CURE FOR ALZHEIMER'S DISEASE. ALL FUNDED RESEARCHERS MAY BE ASKED TO REVIEW OCCASIONAL PROPOSALS ON A TWO-WEEK TIMELINE AS A CONDITION OF RECEIVING FUNDING. THE RESEARCH COMMITTEE OF THE BOARD OF DIRECTORS PROVIDES A FINAL REVIEW TO ENSURE ALL PROCEDURES HAVE BEEN FOLLOWED AND THAT THE PROJECT SERVES THE ORGANIZATION'S MISSION TO FUND RESEARCH ACCELERATING BENEFITS TO CURRENT AND POTENTIAL ALZHEIMER'S PATIENTS. AT LEAST TWO SCIENTIFIC REVIEWERS MUST SUBMIT A POSITIVE REVIEW FOR A PROPOSAL TO BE ACCEPTED. ANY QUESTIONS OR CONCERNS ABOUT THE PROPOSAL BY ANY REVIEWER MAY RESULT IN A REQUEST FOR ITERATION OR REJECTION OF THE PROPOSAL. RESEARCHERS WILL BE ADVISED OF ACCEPTANCE, QUESTIONS, OR REJECTION BUT WILL NOT RECEIVE ANY "SCORE OR ASSESSMENT COMMENTARY FROM REVIEWERS; HOWEVER, SUGGESTIONS OR IDEAS FROM REVIEWERS ARE SYNTHESIZED AND PROVIDED WITHOUT ATTRIBUTION IF A PROPOSAL IS FUNDED. | ExplanationTxt |
Schedule G IRS990ScheduleG
Fundraising Event Information FundraisingEventInformationGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Event1 | FISHER ISLAND GOLF | Event1Nm |
| Gross Receipts Event1 | $340,522 | GrossReceiptsEvent1Amt |
| Charitable Contri Event1 | $236,522 | CharitableContriEvent1Amt |
| Gross Revenue Event1 | $104,000 | GrossRevenueEvent1Amt |
| Rent Facility Costs Event1 | $66,019 | RentFacilityCostsEvent1Amt |
| Food And Beverage Event1 | $7,227 | FoodAndBeverageEvent1Amt |
| Other Direct Expenses Event1 | $28,485 | OtherDirectExpensesEvent1Amt |
| Gross Receipts Total | $340,522 | GrossReceiptsTotalAmt |
| Charitable Contributions Tot | $236,522 | CharitableContributionsTotAmt |
| Gross Revenue Total Events | $104,000 | GrossRevenueTotalEventsAmt |
| Rent Fclty Costs Total Events | $66,019 | RentFcltyCostsTotalEventsAmt |
| Food And Beverage Total Events | $7,227 | FoodAndBeverageTotalEventsAmt |
| Oth Direct Expnss Total Events | $28,485 | OthDirectExpnssTotalEventsAmt |
| Direct Expense Summary Events | $101,731 | DirectExpenseSummaryEventsAmt |
| Net Income Summary | $2,269 | NetIncomeSummaryAmt |
Schedule I IRS990ScheduleI
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (1) | GrantRecordsMaintainedInd |
Recipient Table RecipientTable (106 entries)
| Address Line1USAddress/AddressLine1Txt | CityUSAddress/CityNm | State AbbreviationUSAddress/StateAbbreviationCd | ZIPUSAddress/ZIPCd | Recipient EINRecipientEIN | IRC SectionIRCSectionDesc | Cash GrantCashGrantAmt | Non Cash AssistanceNonCashAssistanceAmt | Purpose Of GrantPurposeOfGrantTxt | Address Line2USAddress/AddressLine2Txt |
|---|---|---|---|---|---|---|---|---|---|
| BAYLOR COLLEGE OF MEDICINE | |||||||||
| 1 BAYLOR PLAZA | HOUSTON | TX | 77030 | 741613878 | 501 (C)(3) | $138,000 | $0 | DECIPHER THE ASTROCYTE CELL-SURFACE PROTEOME IN ALZHEIMER'S DISEASE | |
| BETH ISRAEL DEADONESS MEDICAL CENTER | |||||||||
| 330 BROOKLINE AVENUE | BOSTON | MA | 022155491 | 042103881 | 501 (C)(3) | $201,235 | $0 | INTEGRATING SINGLE-CELL GENOMICS FOR PATHWAYS TO PROTECTION AND RESILIENCE AGAINST ALZHEIMER'S DISEASE | |
| BOSTON CHILDREN'S HOSPITAL | |||||||||
| 300 LONGWOOD AVE | BOSTON | MA | 02215 | 042774441 | 501 (C)(3) | $86,250 | $0 | BEE: NEUROINFLAMMATION AT THE CHOROID PLEXUS IN ALZHEIMER'S DISEASE - SUPPLEMENT TO YR 1 (OF2) | |
| BRIGHAM AND WOMEN'S HOSPITAL | |||||||||
| 75 FRANCIS STREET | BOSTON | MA | 02215 | 042312909 | 501 (C)(3) | $575,000 | $0 | APOE: APOE4 ACCELERATES CD8 EXHAUSTION VIA GLUCOCORTICOID SIGNALING IN ALZHEIMER'S FEMALE CARRIERS | |
| BRIGHAM AND WOMEN'S HOSPITAL | |||||||||
| 75 FRANCIS STREET | BOSTON | MA | 02215 | 042312909 | 501 (C)(3) | $275,500 | $0 | MBC: HARNESSING DIET-MICROBE INTERACTIONS TO PREVENT ALZHEIMER'S DISEASE PATHOGENESIS | |
| BRIGHAM AND WOMEN'S HOSPITAL | |||||||||
| 75 FRANCIS STREET | BOSTON | MA | 02215 | 042312909 | 501 (C)(3) | $201,250 | $0 | ROLE OF CHECKPOINT MOLECULES TIM-3 AND LAG-3 IN MICROGLIAL FUNCTION IN ALZHEIMER'S DISEASE | |
| BRIGHAM AND WOMEN'S HOSPITAL | |||||||||
| 75 FRANCIS STREET | BOSTON | MA | 02215 | 042312909 | 501 (C)(3) | $228,779 | $0 | DO CLASSICAL COMPLEMENT ACTIVATION AND THE ROUTE OF ADMINISTRATION OF ANTI-AMYLOID ANTIBODIES CONTRIBUTE TO VASCULAR SIDE EFFECTS KNOWN AS ARIA? | |
| BRIGHAM AND WOMEN'S HOSPITAL | |||||||||
| 75 FRANCIS STREET | BOSTON | MA | 02215 | 042312909 | 501 (C)(3) | $195,250 | $0 | TARGETING NEUROINFLAMMATION WITH NASAL ADMINISTRATION OF ANTI-CD3 MONOCLONAL ANTIBODY TO TREAT ALZHEIMER'S DISEASE | |
| BRIGHAM AND WOMEN'S HOSPITAL | |||||||||
| 75 FRANCIS STREET | BOSTON | MA | 02215 | 042312909 | 501 (C)(3) | $201,234 | $0 | T CELL MODULATION OF MICROGLIA TO TREAT ALZHEIMER'S DISEASE | |
| BURKE NEUROLOGICAL INSTITUTE | |||||||||
| 785 MAMARONECK AVE | WHITE PLAINS | NY | 106052523 | 133434924 | 501 (C)(3) | $173,007 | $0 | 2-DEOXYGLUCOSE AND ITS ANALOGS AS NOVEL THERAPEUTICS TO BUILD RESILIENCE TO ALZHEIMER'S DISEASE | |
| CARNEGIE MELLON UNIVERSITY | |||||||||
| 5000 FORBES AVE | PITTSBURGH | PA | 15213 | 250969449 | 501 (C)(3) | $201,250 | $0 | INTERPRETING ALZHEIMER'S DISEASE-ASSOCIATED GENETIC VARIATION AT ENHANCER REGIONS | |
| COLUMBIA UNIVERSITY | |||||||||
| 630 WEST 168TH STREET BOX 49 | NEW YORK | NY | 10032 | 135598093 | 501 (C)(3) | $201,279 | $0 | NEUROPROTEASOMES MECHANISTICALLY CONNECT APOE ISOFORMS TO ENDOGENOUS TAU AGGREGATION | |
| DANA-FARBER CANCER INSTITUTE INC | |||||||||
| 450 BROOKLINE AVENUE BP418 | BOSTON | MA | 02215 | 042263040 | 501 (C)(3) | $201,250 | $0 | PRE-CLINICAL TESTING OF CDK4/6 INHIBITORS AS A THERAPEUTIC STRATEGY IN ALZHEIMER'S DISEASE USING AD TAUOPATHY MOUSE MODEL | |
| DUKE UNIVERSITY SCHOOL OF MEDICINE | |||||||||
| 324 BLACKWELL STREET SUITE 900 | DURHAM | NC | 27701 | 562247203 | 501 (C)(3) | $268,750 | $0 | PLASMA PROTEINS, SEX AND ALZHEIMER'S DIEASE: PROTEOMEWIDE ANALYSES OF THE UK BIOBANK AND FRAMINGHAM HEART STUDY | |
| DUKE UNIVERSITY SCHOOL OF MEDICINE | |||||||||
| 324 BLACKWELL STREET SUITE 900 | DURHAM | NC | 27701 | 562247203 | 501 (C)(3) | $192,314 | $0 | CONTRIBUTIONS OF IL34 SIGNALING TO MICROGLIAL FUNCTION AND ALZHEIMER'S PATHOLOGY IN MICE | |
| DUKE UNIVERSITY SCHOOL OF MEDICINE | |||||||||
| 324 BLACKWELL STREET SUITE 900 | DURHAM | NC | 27701 | 562247203 | 501 (C)(3) | $24,957 | $0 | UTILITY OF BLOOD BASED MARKERS FOR PREDICTING ARIA AND ITS COURSE IN MCI AND AD SUBJECTS UNDERGOING ROUTINE CLINICAL TREATMENT WITH AMYLOID-DIRECTED ANTIBODIES | |
| GLADSTONE INSTITUTES | |||||||||
| 1650 OWENS STREET | SAN FRANCISCO | CA | 94158 | 237203666 | 501 (C)(3) | $201,250 | $0 | UNDERSTANDING HOW HUMAN BRAIN VASCULAR CELLS MEDIATE GENETIC RISK FOR ALZHEIMER'S DISEASE | |
| ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | |||||||||
| ONE GUSTAVE L LEVY PLACE BOX 1075 | NEW YORK | NY | 10029 | 136171197 | 501 (C)(3) | $201,250 | $0 | ROLE OF PSYCHOSOCIAL STRESS IN ALZHEIMER'S DISEASE | |
| ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | |||||||||
| ONE GUSTAVE L LEVY PLACE BOX 1075 | NEW YORK | NY | 10029 | 136171197 | 501 (C)(3) | $172,500 | $0 | VGF-DERIVED PEPTIDE THERAPY FOR AD: STUDIES OF MOUSE AND HUMAN TLQP-21 AND ITS RECEPTOR, C3AR1 | |
| ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | |||||||||
| ONE GUSTAVE L LEVY PLACE BOX 1075 | NEW YORK | NY | 10029 | 136171197 | 501 (C)(3) | $201,250 | $0 | INVESTIGATING THE ASSOCIATION BETWEEN CLONAL HEMATOPOIESIS AND ALZHEIMER'S DISEASE | |
| ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | |||||||||
| ONE GUSTAVE L LEVY PLACE BOX 1075 | NEW YORK | NY | 10029 | 136171197 | 501 (C)(3) | $201,250 | $0 | INVESTIGATING LYSOSOMAL MECHANISMS OF RISK AND RESILIENCE IN ALZHEIMER'S DISEASE | |
| ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | |||||||||
| ONE GUSTAVE L LEVY PLACE BOX 1075 | NEW YORK | NY | 10029 | 136171197 | 501 (C)(3) | $150,786 | $0 | ALZHEIMER'S DISEASE PET IMAGING OF NONFIBRILLAR AMYLOID BETA AGGREGATES USING AZAPEPTIDE (AZP) TRACER | |
| INDIANA UNIVERSITY | |||||||||
| 1024 E 3RD STREET ROOM 132 | BLOOMINGTON | IN | 47405 | 356001673 | 501 (C)(3) | $200,631 | $0 | MODULATING THE LEVELS OF TAU-SEED INTERACTORS TO TREAT ALZHEIMER'S DISEASES | |
| INDIANA UNIVERSITY | |||||||||
| 1024 E 3RD STREET ROOM 132 | BLOOMINGTON | IN | 47405 | 356001673 | 501 (C)(3) | $180,419 | $0 | RELATIONSHIP BETWEEN ALZHEIMER'S DISEASE RISK AND OUTCOMES OF MILD REPETITIVE NEUROTRAUMA | |
| MASSACHUSETTS GENERAL HOSPITAL | |||||||||
| 125 NASHUA ST SUITE 540 | BOSTON | MA | 02114 | 041564655 | 501 (C)(3) | $201,250 | $0 | ROLE OF RIN3 AND BIN1 INTERACTION IN THE NEURONS FOR ALZHEIMER'S DISEASE DEVELOPMENT | |
| MASSACHUSETTS GENERAL HOSPITAL | |||||||||
| 125 NASHUA ST SUITE 540 | BOSTON | MA | 02114 | 041564655 | 501 (C)(3) | $201,250 | $0 | ROLE OF STABILIZATION OF MAMS AND MAM-ASSOCIATED PALMITOYLATED APP (MAM-PALAPP) IN ALZHEIMER'S DISEASE | |
| MASSACHUSETTS GENERAL HOSPITAL | |||||||||
| 125 NASHUA ST SUITE 540 | BOSTON | MA | 02114 | 041564655 | 501 (C)(3) | $172,500 | $0 | NEUROPROTECTIVE EFFECTS OF THE EXERCISE HORMONE IRISIN IN ALZHEIMER'S DISEASE | |
| MASSACHUSETTS GENERAL HOSPITAL | |||||||||
| 125 NASHUA ST SUITE 540 | BOSTON | MA | 02114 | 041564655 | 501 (C)(3) | $201,250 | $0 | VALIDATION AND CHARACTERIZATION OF COMPOUNDS MODULATING NEUROINFLAMMATION AND AMYLOID BETA UPTAKE IN MICROGLIAL CELLS | |
| MASSACHUSETTS GENERAL HOSPITAL | |||||||||
| 125 NASHUA ST SUITE 540 | BOSTON | MA | 02114 | 041564655 | 501 (C)(3) | $201,250 | $0 | ROLE OF CD8+ T CELL-GLIAL INTERACTIONS IN MEDIATING ALZHEIMER'S DISEASE PATHOGENESIS | |
| MASSACHUSETTS GENERAL HOSPITAL | |||||||||
| 125 NASHUA ST SUITE 540 | BOSTON | MA | 02114 | 041564655 | 501 (C)(3) | $1,955,000 | $0 | THE CUREALZ ALZHEIMER'S GENOME PROJECT | |
| MASSACHUSETTS GENERAL HOSPITAL | |||||||||
| 125 NASHUA ST SUITE 540 | BOSTON | MA | 02114 | 041564655 | 501 (C)(3) | $287,500 | $0 | MBC: MICROBIAL PROFILING OF HUMAN BRAIN AND GUT MICROBIOMES IN ALZHEIMER'S DISEASE. | |
| MASSACHUSETTS GENERAL HOSPITAL | |||||||||
| 125 NASHUA ST SUITE 540 | BOSTON | MA | 02114 | 041564655 | 501 (C)(3) | $287,500 | $0 | BEE: HUMAN 3D NEURO-VASCULAR INTERACTION AND MENINGEAL LYMPHATICS MODELS WITH APPLICATION TO ALZHEIMER'S DISEASE | |
| MASSACHUSETTS GENERAL HOSPITAL | |||||||||
| 125 NASHUA ST SUITE 540 | BOSTON | MA | 02114 | 041564655 | 501 (C)(3) | $201,250 | $0 | TAU AND B-AMYLOID ARE INNATE IMMUNE ANTIMICROBIAL PEPTIDES IN THE BRAIN | |
| MASSACHUSETTS GENERAL HOSPITAL | |||||||||
| 125 NASHUA ST SUITE 540 | BOSTON | MA | 02114 | 041564655 | 501 (C)(3) | $125,000 | $0 | THE IMPACT OF MUTATIONS IN THE LIGAND-BINDING DOMAIN OF CD33 ON ALZHEIMER'S DISEASE PATHOGENESIS | |
| MASSACHUSETTS GENERAL HOSPITAL | |||||||||
| 125 NASHUA ST SUITE 540 | BOSTON | MA | 02114 | 041564655 | 501 (C)(3) | $201,250 | $0 | EXPLORING NOVEL DRUG CANDIDATES FOR ALZHEIMER'S DISEASE THROUGH INTEGRATIVE PATHWAY ANALYSIS AND VALIDATION IN 3D CELLULAR MODELS | |
| MASSACHUSETTS GENERAL HOSPITAL | |||||||||
| 125 NASHUA ST SUITE 540 | BOSTON | MA | 02114 | 041564655 | 501 (C)(3) | $201,250 | $0 | CHARACTERIZING GUT BACTERIOME-MYCOBIOME SYNERGY IN CORRELATION TO AMYLIN-AB ANTIMICROBIAL SYNERGY IN ALZHEIMER'S DISEASE (AD) IN AD MOUSE MODELS | |
| MASSACHUSETTS GENERAL HOSPITAL | |||||||||
| 125 NASHUA ST SUITE 540 | BOSTON | MA | 02114 | 041564655 | 501 (C)(3) | $230,000 | $0 | ADAM10 CLEAVAGE OF APP: PHYSIOLOGICAL FUNCTION IN BRAIN AND THERAPEUTIC POTENTIAL FOR ALZHEIMER'S DISEASE | |
| MASSACHUSETTS GENERAL HOSPITAL | |||||||||
| 125 NASHUA ST SUITE 540 | BOSTON | MA | 02114 | 041564655 | 501 (C)(3) | $201,250 | $0 | CHARACTERIZATION OF CNS-PENETRANT HDAC 11 SELECTIVE INHIBITORS IN ALZHEIMER'S DISEASE MODELS | |
| MASSACHUSETTS GENERAL HOSPITAL | |||||||||
| 55 FRUIT STREET | BOSTON | MA | 02114 | 042697983 | 501 (C)(3) | $230,000 | $0 | SELECTIVE VULNERABILITY IN POSTERIOR CORTICAL ATROPHY | |
| MASSACHUSETTS GENERAL HOSPITAL | |||||||||
| 55 FRUIT STREET | BOSTON | MA | 02114 | 042697983 | 501 (C)(3) | $300,000 | $0 | UNDERSTANDING HUMAN BRAIN RESILIENCE TO ALZHEIMER'S PATHOLOGY | |
| MASSACHUSETTS GENERAL HOSPITAL | |||||||||
| 55 FRUIT STREET | BOSTON | MA | 02114 | 042697983 | 501 (C)(3) | $287,500 | $0 | ALZHEIMER'S DISEASE TAU CONSORTIUM: TOXIC CONSEQUENCES OF EARLY TAU SEEDING | |
| MASSACHUSETTS GENERAL HOSPITAL | |||||||||
| 55 FRUIT STREET | BOSTON | MA | 02114 | 042697983 | 501 (C)(3) | $201,227 | $0 | CIRCUIT DYNAMICS IN APOE4 MICE | |
| MASSACHUSETTS GENERAL HOSPITAL | |||||||||
| 55 FRUIT STREET | BOSTON | MA | 02114 | 042697983 | 501 (C)(3) | $201,250 | $0 | GROWTH, CHARACTERIZATION, AND DISTRIBUTION OF A NEURODEGENERATIVE DISEASE-FOCUSED FIBROBLAST/IPS CELL BANK TO SUPPORT MOLECULAR MODELS OF PATIENT-SPECIFIC VARIATION WITH VALIDATION IN MATCHED DONATED BRAIN TISSUES | |
| MASSACHUSETTS GENERAL HOSPITAL | |||||||||
| 55 FRUIT STREET | BOSTON | MA | 02114 | 042697983 | 501 (C)(3) | $172,500 | $0 | NEUROPROTECTIVE EFFECTS OF THE EXERCISE HORMONE IRISIN IN ALZHEIMER'S DISEASE | |
| MASSACHUSETTS INSTITUTE OF TECHNOLOGY | |||||||||
| 77 MASSACHUSETTS AVENUE | CAMBRIDGE | MA | 02139 | 042103594 | 501 (C)(3) | $300,000 | $0 | DISSECTING MICROGLIAL STATE DYNAMICS IN ALZHEIMER'S DISEASE | |
| MAYO CLINIC JACKSONVILLE | |||||||||
| 4500 SAN PABLO ROAD | JACKSONVILLE | FL | 322241865 | 593337028 | 501 (C)(3) | $201,250 | $0 | RESTORE MENINGEAL LYMPHATIC DRAINAGE TO ALLEVIATE WHITE MATTER DAMAGE AND CEREBRAL AMYLOID ANGIOPATHY IN A MODEL OF ALZHEIMER'S DISEASE | |
| MAYO CLINIC JACKSONVILLE | |||||||||
| 4500 SAN PABLO ROAD | JACKSONVILLE | FL | 322241865 | 593337028 | 501 (C)(3) | $201,250 | $0 | EVALUATING THE CONTRIBUTION OF TDP-43 DYSFUNCTION AND CRYPTIC MIS-SPLICING TO AD PATHOGENESIS | |
| MEDICAL COLLEGE OF WISCONSIN | |||||||||
| 8701 WATERTOWN PLANK ROAD | MILWAUKEE | WI | 53226 | 390806261 | 501 (C)(3) | $4,721 | $0 | RELATIONSHIP BETWEEN ALZHEIMER'S DISEASE RISK AND OUTCOMES OF MILD REPETITIVE NEUROTRAUMA | |
| MEMORIAL SLOAN KETTERING CANCER CENTER | |||||||||
| 1275 YORK AVE | NEW YORK | NY | 10065 | 131924236 | 501 (C)(3) | $230,000 | $0 | THE ROLE OF IFITM3 AND -SECRETASE IN MICROGLIA | |
| NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS & STROKE | |||||||||
| 900 ROCKVILLE PIKE | BETHESDA | MD | 20892 | 520858115 | 501 (C)(3) | $287,500 | $0 | BEE: HIGH-RESOLUTION MRI OF THE BRAIN BORDERS | |
| NEW YORK UNIVERSITY SCHOOL OF MEDICINE | |||||||||
| 550 FIRST AVE | NEW YORK | NY | 10016 | 135562308 | 501 (C)(3) | $287,500 | $0 | NEUROIMMUNE CONSORTIUM: ASTROCYTE INFLAMMATORY CONTRIBUTIONS TO ALZHEIMER'S DISEASE | |
| NEW YORK UNIVERSITY SCHOOL OF MEDICINE | |||||||||
| 550 FIRST AVE | NEW YORK | NY | 10016 | 135562308 | 501 (C)(3) | $201,250 | $0 | MIDLIFE AUTOANTIBODY PROFILES AND THE RISK OF LATE ONSET ALZHEIMER'S DISEASE IN WOMEN | |
| NORTHWESTERN UNIVERSITY | |||||||||
| 710 N LAKE SHORE DR ABBOTT 1416 | CHICAGO | IL | 60611 | 362167817 | 501 (C)(3) | $286,559 | $0 | ALZHEIMER'S DISEASE TAU CONSORTIUM: THE ROLE OF AB - INDUCED MEMBRANE DAMAGE IN TAU PATHOLOGY | |
| NORTHWESTERN UNIVERSITY | |||||||||
| 710 N LAKE SHORE DR ABBOTT 1416 | CHICAGO | IL | 60611 | 362167817 | 501 (C)(3) | $345,000 | $0 | MBC: INTERACTION OF THE MICROBIOME WITH ASTROCYTES AND AMYLOID PATHOLOGY | |
| PRESIDENT AND FELLOWS OF HARVARD COLLEGE | |||||||||
| 1033 MASSACHUSETTS AVE 3RD FLOOR | CAMBRIDGE | MA | 02138 | 042103580 | 501 (C)(3) | $201,250 | $0 | HARVARD MEDICAL SCHOOL-DEFINING A ROLE FOR THE MS4A GENES IN ALZHEIMER'S DISEASE | |
| PRESIDENT AND FELLOWS OF HARVARD COLLEGE | |||||||||
| 1033 MASSACHUSETTS AVE 3RD FLOOR | CAMBRIDGE | MA | 02138 | 042103580 | 501 (C)(3) | $201,250 | $0 | HARVARD MEDICAL SCHOOL-DISSECTING THE MODULATORY ROLES OF IL-17RD IN ALZHEIMER'S DISEASE | |
| PRESIDENT AND FELLOWS OF HARVARD COLLEGE | |||||||||
| 1033 MASSACHUSETTS AVE 3RD FLOOR | CAMBRIDGE | MA | 02138 | 042103580 | 501 (C)(3) | $201,250 | $0 | HARVARD MEDICAL SCHOOL-MENINGEAL TREGS IN INDIVIDUALS WITH VS WITHOUT ALZHEIMER'S DISEASE | |
| PRESIDENT AND FELLOWS OF HARVARD COLLEGE | |||||||||
| 1033 MASSACHUSETTS AVE 3RD FLOOR | CAMBRIDGE | MA | 02138 | 042103580 | 501 (C)(3) | $230,000 | $0 | HARVARD T.H. CHAN SCHOOL OF PUBLIC HEALTH-MOVING THE CURE ALZHEIMER GENOME PROJECT BEYOND SIMPLE ASSOCIATIONS: INTEGRATING FUNCTIONAL INFORMATION, FINE-MAPPING AND CAUSAL INFERENCE APPROACHES INTO THE FAMILY-BASED ANALYSIS OF THE CURE ALZHEIMER WHOLE-GENOME SEQUENCING (WGS) FAMILY STUDY | |
| PRESIDENT AND FELLOWS OF HARVARD COLLEGE | |||||||||
| 1033 MASSACHUSETTS AVE 3RD FLOOR | CAMBRIDGE | MA | 02138 | 042103580 | 501 (C)(3) | $187,315 | $0 | HARVARD T.H. CHAN SCHOOL OF PUBLIC HEALTH-PRECISION MEDICINE PREDICTION MODEL FOR ALZHEIMER'S DISEASE USING COOPERATIVE LEARNING APPROACHES FOR MULTI-OMIC DATA | |
| ST JUDE CHILDREN'S RESEARCH HOSPITAL | |||||||||
| 262 DANNY THOMAS PLACE | MEMPHIS | TN | 38105 | 620646012 | 501 (C)(3) | $92,000 | $0 | DECIPHER THE ASTROCYTE CELL-SURFACE PROTEOME IN ALZHEIMER'S DISEASE | |
| STANFORD UNIVERSITY | |||||||||
| 485 BROADWAY | REDWOOD CITY | CA | 94063 | 941156365 | 501 (C)(3) | $201,250 | $0 | MULTIOMICS CHARACTERIZATION OF TAU PATHOLOGY ONSET AND ITS RELATIONSHIP WITH AMYLOID IN THE HUMAN HIPPOCAMPUS | |
| THE BROAD INSTITUTE INC | |||||||||
| 415 MAIN STREET | CAMBRIDGE | MA | 02142 | 263428781 | 501 (C)(3) | $230,000 | $0 | INVESTIGATING ALZHEIMER'S DISEASE-ASSOCIATED MEMBRANE BIOLOGY IN MICROGLIA AND NEURONS | |
| THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO | |||||||||
| 490 ILLINOIS STREET 4TH FLOOR | SAN FRANCISCO | CA | 94143 | 943067788 | 501 (C)(3) | $201,250 | $0 | PROBING THE MOLECULAR UNDERPINNINGS OF G PROTEIN-COUPLED RECEPTOR ADGRG1 MEDIATED PROTECTIVE MICROGLIAL RESPONSES TO ALZHEIMER'S DISEASE | |
| THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO | |||||||||
| 490 ILLINOIS STREET 4TH FLOOR | SAN FRANCISCO | CA | 94143 | 943067788 | 501 (C)(3) | $201,250 | $0 | ROLE OF THE CIRCULATING EXERKINE GPLD1 IN AMELIORATING ALZHEIMER'S DISEASE PATHOLOGY | |
| THE SALK INSTITUTE FOR BIOLOGICAL STUDIES | |||||||||
| 10010 NORTH TORREY PINES ROAD | LA JOLLA | CA | 92037 | 952160097 | 501 (C)(3) | $201,250 | $0 | THE ROLE OF ASTROCYTE-SECRETED LGFBP2 IN THE PROGRESSION OF ALZHEIMER'S DISEASE | |
| THE SALK INSTITUTE FOR BIOLOGICAL STUDIES | |||||||||
| 10010 NORTH TORREY PINES ROAD | LA JOLLA | CA | 92037 | 952160097 | 501 (C)(3) | $201,250 | $0 | TO ELUCIDATE THE ROLE OF MEMORY T CELLS AS A DETERMINANT OF AGE-RELATED INFLAMMATION IN ALZHEIMER'S DISEASE | |
| THE UNIVERSITY OF CHICAGO | |||||||||
| 5801 SOUTH ELLIS AVE | CHICAGO | IL | 60637 | 362177139 | 501 (C)(3) | $216,287 | $0 | IDENTIFYING THE SEX-SPECIFIC ROLES OF THE GUTMICROBIOME-BRAIN AXIS IN A MOUSE MODEL OF AB AMYLOIDOSIS | |
| THE UNIVERSITY OF CHICAGO | |||||||||
| 5801 SOUTH ELLIS AVE | CHICAGO | IL | 60637 | 362177139 | 501 (C)(3) | $250,000 | $0 | MICROBIOME CONSORTIUM: TEMPORAL RELATIONSHIPS BETWEEN GUT DYSBIOSIS, BRAIN AB METABOLISM AND MICROGLIA CELL ACTIVATION FOLLOWING ANTIBIOTIC TREATMENT | |
| THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO | |||||||||
| 7703 FLOYD CURL DRIVE MSC 7828 | SAN ANTONIO | TX | 78229 | 741586031 | 501 (C)(3) | $201,250 | $0 | IDENTIFICATION AND VALIDATION OF PLASMA-BASED LIPID BIOMARKERS FOR EARLY ALZHEIMER'S DISEASE IN THE UNIQUE, PRIMARILY HISPANIC, SOUTH TEXAS POPULATION | |
| UNIVERISTY OF CALIFORNIA LOS ANGELES | |||||||||
| 10920 WILSHIRE BOULEVARD SUITE 600 | LOS ANGELES | CA | 90024 | 956006143 | 501 (C)(3) | $201,250 | $0 | NOVEL AI DECODES AGING NEURONS | |
| UNIVERSITY OF CALIFORNIA DAVIS | |||||||||
| ONE SHIELDS AVENUE | DAVIS | CA | 95616 | 943067788 | 501 (C)(3) | $285,851 | $0 | NEUROIMMUNE CONSORTIUM: IMPACT OF AD POLYGENIC RISK SCORE ON MICROGLIAL RESPONSE TO PERIPHERAL INFLAMMATION | |
| UNIVERSITY OF CALIFORNIA IRVINE | |||||||||
| 228 ALDRICH HALL | IRVINE | CA | 92697 | 952226406 | 501 (C)(3) | $201,250 | $0 | BIOINFORMATICS PLATFORM FOR MODELING ALZHEIMER'S PROGRESSION (MAP-AD PLATFORM) | |
| UNIVERSITY OF CALIFORNIA IRVINE | |||||||||
| 228 ALDRICH HALL | IRVINE | CA | 92697 | 952226406 | 501 (C)(3) | $230,000 | $0 | ENDOGENOUS HUMAN ANTIBODIES ASSOCIATED WITH ALZHEIMER'S DISEASE | |
| UNIVERSITY OF CALIFORNIA SAN DIEGO | |||||||||
| 9500 GILMAN DRIVE MC 0934 | LA JOLLA | CA | 920930636 | 952872494 | 501 (C)(3) | $287,500 | $0 | BEE: HOW DOES VASCULAR FATTY ACID METABOLISM REGULATE THE PATHOPHYSIOLOGY OF ALZHEIMER'S DISEASE? | |
| UNIVERSITY OF CALIFORNIA SAN DIEGO | |||||||||
| 9500 GILMAN DRIVE MC 0934 | LA JOLLA | CA | 920930636 | 952872494 | 501 (C)(3) | $201,250 | $0 | DYSREGULATION OF SIGNALING ON POST SYNAPTIC DENSITY SCAFFOLDS IN ALZHEIMER'S DISEASE | |
| UNIVERSITY OF MIAMI | |||||||||
| PO BOX 405803 | ATLANTA | GA | 30384 | 590624458 | 501 (C)(3) | $24,589 | $0 | 2-DEOXYGLUCOSE AND ITS ANALOGS AS NOVEL THERAPEUTICS TO BUILD RESILIENCE TO ALZHEIMER'S DISEASE | |
| UNIVERSITY OF MICHIGAN | |||||||||
| 3003 SOUTH STATE STREET | ANN ARBOR | MI | 481091287 | 386006309 | 501 (C)(3) | $148,773 | $0 | NON-INVASIVE DELIVERY OF IL-2 TO THE CNS FOR LOCAL EXPANSION OF TREGS AND PREVENTION OF NEURODEGENERATION IN TAUOPATTHY | |
| UNIVERSITY OF PENNSYLVANIA | |||||||||
| 3451 WALNUT STREET 5TH FLOOR | PHILADELPHIA | PA | 191046205 | 231352685 | 501 (C)(3) | $285,952 | $0 | APOE: CELL AUTONOMOUS ROLES OF PROTECTIVE APOE VARIANTS IN MICROGLIA RESPONDING TO AMYLOID PATHOLOGY | FRANKLIN BLDG |
| UNIVERSITY OF RHODE ISLAND | |||||||||
| 75 LOWER COLLEGE ROAD | KINGSTON | RI | 02881 | 223011455 | 501 (C)(3) | $201,250 | $0 | EFFECT OF APOE GENOTYPE IN A NOVEL RAT MODEL OF CEREBRAL AMYLOID ANGIOPATHY - YEAR 2/2 | |
| UNIVERSITY OF ROCHESTER | |||||||||
| 910 GENESEE STREET SUITE 200 | ROCHESTER | NY | 146113847 | 160743209 | 501 (C)(3) | $287,500 | $0 | BEE: DOES SLYM FAILURE COMPROMISE GLYMPHATIC CLEARANCE IN ALZHEIMER'S DISEASE? | |
| UNIVERSITY OF SOUTHERN CALIFORNIA | |||||||||
| 3500 S FIGUEROA STREET SUITE 102 | LOS ANGELES | CA | 900898001 | 951642394 | 501 (C)(3) | $227,410 | $0 | PROTECTION AGAINST ALZHEIMER'S WITH LONGEVITY-PROMOTING INTERVENTION 17A-ESTRADIOL | |
| UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER | |||||||||
| 5323 HARRY HINES BLVD | DALLAS | TX | 75390 | 756002868 | 501 (C)(3) | $287,276 | $0 | ALZHEIMER'S DISEASE TAU CONSORTIUM: STRAIN REPLICATION IN MOUSE AND CELL MODELS | |
| UNIVERSITY OF VIRGINIA | |||||||||
| 1001 N EMMETT ST | CHARLOTTESVILLE | VA | 229044195 | 546001796 | 501 (C)(3) | $201,250 | $0 | IMPACT OF DNA DAMAGE-MEDIATED STING ACTIVATION ON MYELIN FUNCTION IN AN ALZHEIMER'S DISEASE ANIMAL MODEL | |
| UNIVERSITY OF VIRGINIA | |||||||||
| 1001 N EMMETT ST | CHARLOTTESVILLE | VA | 229044195 | 546001796 | 501 (C)(3) | $201,250 | $0 | ELUCIDATING THE ROLE OF CLEC7A IN TAU-MEDIATED NEURODEGENERATIVE DISEASE | |
| UNIVERSITY OF WASHINGTON | |||||||||
| 4300 ROOSEVELT WAY NE BOX 354965 | SEATTLE | WA | 98105 | 916001537 | 501 (C)(3) | $201,250 | $0 | ELUCIDATING THE THERAPEUTIC POTENTIAL OF THE ENDOLYSOSOME PATHWAY FOR ALZHEIMER'S DISEASE | |
| WAKE FOREST UNIVERSITY HEALTH SCIENCES | |||||||||
| MEDICAL CENTER BOULEVARD | WINSTONSALEM | NC | 27157 | 223849199 | 501 (C)(3) | $201,250 | $0 | INVESTIGATING THE ROLE OF TAU PROTEIN IN NEURONAL SENESCENCE | |
| WASHINGTON UNIVERSITY IN ST LOUIS | |||||||||
| 1 BROOKINGS DRIVE | ST LOUIS | MO | 63130 | 430653611 | 501 (C)(3) | $201,250 | $0 | IDENTIFYING AGE-RELATED PROTEOMIC CHANGES THAT PREDICT FUTURE ONSET OF AMYLOID-BETA AGGREGATION IN LATE ONSET ALZHEIMER'S DISEASE | |
| WASHINGTON UNIVERSITY IN ST LOUIS | |||||||||
| 1 BROOKINGS DRIVE | ST LOUIS | MO | 63130 | 430653611 | 501 (C)(3) | $219,578 | $0 | MAPPING THE X CHROMOSOME MULTI-OME IN ALZHEIMER'S AND PARKINSON'S DISEASE | |
| WASHINGTON UNIVERSITY IN ST LOUIS | |||||||||
| 1 BROOKINGS DRIVE | ST LOUIS | MO | 63130 | 430653611 | 501 (C)(3) | $201,250 | $0 | DEVELOPMENT OF SMALL MOLECULE INHIBITORS OF CHOLESTEROL 25-HYDROXYLASE | |
| WASHINGTON UNIVERSITY IN ST LOUIS | |||||||||
| 1 BROOKINGS DRIVE | ST LOUIS | MO | 63130 | 430653611 | 501 (C)(3) | $200,356 | $0 | MULTIOMIC AND FUNCTIONAL CHARACTERIZATION OF STREM2 MODIFIERS | |
| WASHINGTON UNIVERSITY IN ST LOUIS | |||||||||
| 1 BROOKINGS DRIVE | ST LOUIS | MO | 63130 | 430653611 | 501 (C)(3) | $201,250 | $0 | TARGETING REACTIVE ASTROCYTES AMPK SIGNALING TO SUPPRESS INFLAMMATION IN ALZHEIMER'S DISEASE | |
| WASHINGTON UNIVERSITY IN ST LOUIS | |||||||||
| 1 BROOKINGS DRIVE | ST LOUIS | MO | 63130 | 430653611 | 501 (C)(3) | $201,250 | $0 | ANTIVIRAL T CELL INFILTRATION TO THE MENINGES AND BRAIN INFLUENCES NEURODEGENERATION IN ALZHEIMER'S DISEASE | |
| WASHINGTON UNIVERSITY IN ST LOUIS | |||||||||
| 1 BROOKINGS DRIVE | ST LOUIS | MO | 63130 | 430653611 | 501 (C)(3) | $345,000 | $0 | APOE: INVESTIGATING POTENTIAL CELL AUTONOMOUS NEUROPROTECTION OF APOE PROTECTIVE VARIANTS | |
| WASHINGTON UNIVERSITY IN ST LOUIS | |||||||||
| 1 BROOKINGS DRIVE | ST LOUIS | MO | 63130 | 430653611 | 501 (C)(3) | $287,500 | $0 | MBC: THE ROLE OF GUT MICROBIAL METABOLISM IN TAU-MEDIATED NEURODEGENERATION | |
| WASHINGTON UNIVERSITY IN ST LOUIS | |||||||||
| 1 BROOKINGS DRIVE | ST LOUIS | MO | 63130 | 430653611 | 501 (C)(3) | $201,250 | $0 | 2024 MORBY PRIZE | |
| WASHINGTON UNIVERSITY IN ST LOUIS | |||||||||
| 1 BROOKINGS DRIVE | ST LOUIS | MO | 63130 | 430653611 | 501 (C)(3) | $201,250 | $0 | CONTRIBUTION OF SKULL BONE MARROW-DERIVED CELLS TO ALZHEIMER'S DISEASE | |
| WASHINGTON UNIVERSITY IN ST LOUIS | |||||||||
| 1 BROOKINGS DRIVE | ST LOUIS | MO | 63130 | 430653611 | 501 (C)(3) | $345,000 | $0 | BEE: MENINGEAL MAST CELL CONTROL OF CSF DYNAMICS IN HOMEOSTASIS AND ALZHEIMER'S DISEASE | |
| WASHINGTON UNIVERSITY IN ST LOUIS | |||||||||
| 1 BROOKINGS DRIVE | ST LOUIS | MO | 63130 | 430653611 | 501 (C)(3) | $123,098 | $0 | CHARACTERIZATION OF MOLECULAR BIOMARKER PROFILES THROUGHOUT THE PATHOBIOLOGICAL CONTINUUM | |
| WASHINGTON UNIVERSITY IN ST LOUIS | |||||||||
| 1 BROOKINGS DRIVE | ST LOUIS | MO | 63130 | 430653611 | 501 (C)(3) | $201,250 | $0 | SPECIFICITY OF T CELL RESPONSES IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE (ADAD) | |
| WASHINGTON UNIVERSITY IN ST LOUIS | |||||||||
| 1 BROOKINGS DRIVE | ST LOUIS | MO | 63130 | 430653611 | 501 (C)(3) | $52,477 | $0 | NON-INVASIVE DELIVERY OF IL-2 TO THE CNS FOR LOCAL EXPANSION OF TREGS AND PREVENTION OF NEURODEGENERATION IN TAUOPATTHY | |
| WASHINGTON UNIVERSITY IN ST LOUIS | |||||||||
| 1 BROOKINGS DRIVE | ST LOUIS | MO | 63130 | 430653611 | 501 (C)(3) | $258,750 | $0 | DISSECTING ALZHEIMER'S DISEASE PHENOTYPES IN DIRECTLY REPROGRAMMED PATIENT-DERIVED NEURONS | |
| WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY | |||||||||
| 1300 YORK AVENUE | NEW YORK | NY | 100654805 | 136094042 | 501 (C)(3) | $200,532 | $0 | HYPERTENSION, TAU AND NEURODEGENERATION | |
| WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY | |||||||||
| 1300 YORK AVENUE | NEW YORK | NY | 100654805 | 136094042 | 501 (C)(3) | $201,250 | $0 | TAU-INDUCED POSTSYNAPTIC DYSFUNCTION IN TAUOPATHY MODELS | |
| WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY | |||||||||
| 1300 YORK AVENUE | NEW YORK | NY | 100654805 | 136094042 | 501 (C)(3) | $402,500 | $0 | SEX-BIASED TLR7 SIGNALING IN DEMYELINATION AND ITS INHIBITION BY SMALL MOLECULES | |
| WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY | |||||||||
| 1300 YORK AVENUE | NEW YORK | NY | 100654805 | 136094042 | 501 (C)(3) | $201,250 | $0 | IDENTIFICATION AND DEVELOPMENT OF CD33 INHIBITORS AND PRE-RNA SPLICING MODULATORS | |
| YALE UNIVERSITY | |||||||||
| PO BOX 208239 | NEW HAVEN | CT | 065208239 | 060646973 | 501 (C)(3) | $199,995 | $0 | THE ROLE OF CALCIUM HOMEOSTASIS IN AXONAL SPHEROID FORMATION IN ALZHEIMER'S DISEASE | |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total501c3 Org | 47 | Total501c3OrgCnt |
| Total Other Org | 0 | TotalOtherOrgCnt |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART I, LINE 2: | FormAndLineReferenceDesc |
| Explanation | THE RESEARCH LEADERSHIP GROUP REVIEWS EACH PROJECT FOR FIT WITH THE CUREALZ RESEARCH PORTFOLIO, SCIENTIFIC INTEGRITY, AND VALUE TO THE SEARCH FOR A CURE FOR ALZHEIMER'S DISEASE. ALL FUNDED RESEARCHERS MAY BE ASKED TO REVIEW OCCASIONAL PROPOSALS ON A TWO-WEEK TIMELINE AS A CONDITION OF RECEIVING FUNDING. THE RESEARCH COMMITTEE OF THE BOARD OF DIRECTORS PROVIDES A FINAL REVIEW TO ENSURE ALL PROCEDURES HAVE BEEN FOLLOWED AND THAT THE PROJECT SERVES THE ORGANIZATION'S MISSION TO FUND RESEARCH ACCELERATING BENEFITS TO CURRENT AND POTENTIAL ALZHEIMER'S PATIENTS. AT LEAST TWO SCIENTIFIC REVIEWERS MUST SUBMIT A POSITIVE REVIEW FOR A PROPOSAL TO BE ACCEPTED. ANY QUESTIONS OR CONCERNS ABOUT THE PROPOSAL BY ANY REVIEWER MAY RESULT IN A REQUEST FOR ITERATION OR REJECTION OF THE PROPOSAL. RESEARCHERS WILL BE ADVISED OF ACCEPTANCE, QUESTIONS, OR REJECTION BUT WILL NOT RECEIVE ANY "SCORE OR ASSESSMENT COMMENTARY FROM REVIEWERS; HOWEVER, SUGGESTIONS OR IDEAS FROM REVIEWERS ARE SYNTHESIZED AND PROVIDED WITHOUT ATTRIBUTION IF A PROPOSAL IS FUNDED. | ExplanationTxt |
Schedule J IRS990ScheduleJ
| Field | Value | IRS element (for citing) |
|---|---|---|
| Compensation Committee | Yes (X) | CompensationCommitteeInd |
| Independent Consultant | Yes (X) | IndependentConsultantInd |
| Form990 Of Other Organizations | Yes (X) | Form990OfOtherOrganizationsInd |
| Written Employment Contract | Yes (X) | WrittenEmploymentContractInd |
| Compensation Survey | Yes (X) | CompensationSurveyInd |
| Board Or Committee Approval | Yes (X) | BoardOrCommitteeApprovalInd |
| Severance Payment | 0 | SeverancePaymentInd |
| Supplemental Nonqual Rtr Plan | 0 | SupplementalNonqualRtrPlanInd |
| Equity Based Comp Arrngm | 0 | EquityBasedCompArrngmInd |
| Comp Based On Revenue Of Flng Org | 0 | CompBasedOnRevenueOfFlngOrgInd |
| Comp Bsd On Rev Related Orgs | 0 | CompBsdOnRevRelatedOrgsInd |
| Comp Bsd Net Earns Flng Org | 0 | CompBsdNetEarnsFlngOrgInd |
| Comp Bsd Net Earns Rltd Orgs | 0 | CompBsdNetEarnsRltdOrgsInd |
| Any Non Fixed Payments | 0 | AnyNonFixedPaymentsInd |
| Initial Contract Exception | 0 | InitialContractExceptionInd |
Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (10 entries)
| TitleTitleTxt | Base Compensation Filing OrgBaseCompensationFilingOrgAmt | Compensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmt | Bonus Filing OrganizationBonusFilingOrganizationAmount | Bonus Related OrganizationsBonusRelatedOrganizationsAmt | Other Compensation Filing OrgOtherCompensationFilingOrgAmt | Other Compensation Rltd OrgsOtherCompensationRltdOrgsAmt | Deferred Compensation Flng OrgDeferredCompensationFlngOrgAmt | Deferred Comp Rltd OrgsDeferredCompRltdOrgsAmt | Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmt | Nontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmt | Total Compensation Filing OrgTotalCompensationFilingOrgAmt | Total Compensation Rltd OrgsTotalCompensationRltdOrgsAmt | Comp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmt | Comp Report Prior990 Rltd OrgsCompReportPrior990RltdOrgsAmt |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MARGARET E SMITH | ||||||||||||||
| CEO | $407,378 | $0 | $18,942 | $0 | $0 | $0 | $10,350 | $0 | $18,763 | $0 | $455,433 | $0 | $0 | $0 |
| KATHARINE HERMAN | ||||||||||||||
| EVP DEVELOPMENT | $342,381 | $0 | $76,200 | $0 | $0 | $0 | $10,350 | $0 | $19,886 | $0 | $448,817 | $0 | $0 | $0 |
| JULIE HARRIS | ||||||||||||||
| EVP RESEARCH MGMT (TO 12/24) | $276,634 | $0 | $19,725 | $0 | $0 | $0 | $8,891 | $0 | $960 | $0 | $306,210 | $0 | $0 | $0 |
| BARBARA CHAMBERS | ||||||||||||||
| EVP MARKETING & COMM. | $246,348 | $0 | $21,200 | $0 | $0 | $0 | $8,403 | $0 | $14,691 | $0 | $290,642 | $0 | $0 | $0 |
| LISA RAND | ||||||||||||||
| VP MARKETING & COMM. | $194,120 | $0 | $5,200 | $0 | $0 | $0 | $6,268 | $0 | $12,247 | $0 | $217,835 | $0 | $0 | $0 |
| DANIEL HARPER | ||||||||||||||
| VP DEVELOPMENT | $189,293 | $0 | $6,200 | $0 | $0 | $0 | $5,959 | $0 | $6,741 | $0 | $208,193 | $0 | $0 | $0 |
| JOSEPHINE ANTONELLIS | ||||||||||||||
| CFO | $190,226 | $0 | $10,000 | $0 | $0 | $0 | $6,014 | $0 | $1,201 | $0 | $207,441 | $0 | $0 | $0 |
| JOHN SLATTERY | ||||||||||||||
| SVP, PHILANTHROPIC PARTNERSHIPS | $189,592 | $0 | $9,200 | $0 | $0 | $0 | $6,054 | $0 | $929 | $0 | $205,775 | $0 | $0 | $0 |
| MAHUA DASGUPTA | ||||||||||||||
| SR. PHILANTROPIC ADVISOR | $172,055 | $0 | $6,200 | $0 | $0 | $0 | $5,690 | $0 | $19,709 | $0 | $203,654 | $0 | $0 | $0 |
| THIDAPHORN SENGSAVANH | ||||||||||||||
| DIRECTOR OF DEVELOPMENT OPS | $146,855 | $0 | $7,200 | $0 | $0 | $0 | $4,883 | $0 | $19,358 | $0 | $178,296 | $0 | $0 | $0 |
Schedule L IRS990ScheduleL
Bus Tr Involve Interested Prsn BusTrInvolveInterestedPrsnGrp
Name Of Interested NameOfInterested
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | PROPER VILLAINS LLC | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Relationship Description | A PRINCIPAL OF THE INDEPENDENT CONTRACTOR IS THE SPOUSE OF A KEY EMPLOYEE | RelationshipDescriptionTxt |
| Transaction | $250,941 | TransactionAmt |
| Transaction | CREATIVE AND PRODUCTION SERVICES | TransactionDesc |
| Sharing Of Revenues | 0 | SharingOfRevenuesInd |
Schedule M IRS990ScheduleM
Securities Publicly Traded SecuritiesPubliclyTradedGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Non Cash Checkbox | Yes (X) | NonCashCheckboxInd |
| Contribution | 90 | ContributionCnt |
| Noncash Contributions Rpt F990 | $5,629,724 | NoncashContributionsRptF990Amt |
| Method Of Determining Revenues | FMV | MethodOfDeterminingRevenuesTxt |
Real Estate Residential RealEstateResidentialGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Non Cash Checkbox | Yes (X) | NonCashCheckboxInd |
| Contribution | 1 | ContributionCnt |
| Noncash Contributions Rpt F990 | $250,276 | NoncashContributionsRptF990Amt |
| Method Of Determining Revenues | SALE PRICE | MethodOfDeterminingRevenuesTxt |
Other Non Cash Contri Table OtherNonCashContriTableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Non Cash Checkbox | Yes (X) | NonCashCheckboxInd |
| Desc | AUCTION ITEMS | Desc |
| Contribution | 8 | ContributionCnt |
| Noncash Contributions Rpt F990 | $38,750 | NoncashContributionsRptF990Amt |
| Method Of Determining Revenues | FMV | MethodOfDeterminingRevenuesTxt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Any Property That Must Be Held | 0 | AnyPropertyThatMustBeHeldInd |
| Review Process Unusual NC Gifts | Yes (1) | ReviewProcessUnusualNCGiftsInd |
| Third Parties Used | Yes (1) | ThirdPartiesUsedInd |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART I, LINE 32B: | FormAndLineReferenceDesc |
| Explanation | WHEN STOCK IS RECEIVED AS A CONTRIBUTION IT IS SOLD IMMEDIATELY UPON RECEIPT OR SOON THEREAFTER AS IS PRACTICAL THROUGH JP MORGAN AND BANK OF NEW YORK/MELLON. | ExplanationTxt |
Schedule O IRS990ScheduleO
Supplemental Information Detail SupplementalInformationDetail (5 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| FORM 990, PART VI, SECTION A, LINE 4 | THE ORGANIZATION UPDATED ITS BYLAWS TO ESTABLISH THE POSITION OF DIRECTOR EMERITUS. |
| FORM 990, PART VI, SECTION B, LINE 11B | THE FORM 990 IS PREPARED BY THE EXTERNAL AUDITORS AND REVIEWED BY THE CFO. REVISIONS, CORRECTIONS, ETC. ARE MADE AS NECESSARY. ONCE ALL ARE SATISFIED WITH THE FORM, IT IS FINALIZED AND A COPY IS SENT TO ALL BOARD MEMBERS. |
| FORM 990, PART VI, SECTION B, LINE 12C | EACH YEAR THE ORGANIZATION'S CONFLICT OF INTEREST POLICY IS PROVIDED TO ALL OFFICERS, DIRECTORS AND KEY EMPLOYEES. THESE PEOPLE ARE ASKED TO REVIEW THE POLICY AND SIGN A STATEMENT INDICATING THAT THEY UNDERSTAND THE POLICY AND HAVE REPORTED ALL POTENTIAL CONFLICTS DURING THE PAST YEAR IN ACCORDANCE WITH THE POLICY AND WILL REPORT ALL POTENTIAL CONFLICTS DURING THE COMING YEAR. ALL POTENTIAL CONFLICTS ARE EVALUATED BY THE BOARD TO DETERMINE IF A CONFLICT ACTUALLY EXISTS. IN THOSE INSTANCES WHERE THE POTENTIAL TRANSACTION IS A CONFLICT, THE BOARD EXAMINES THE TRANSACTION AND A VOTE IS TAKEN (WITH THOSE INVOLVED RECUSING THEMSELVES) AS TO WHETHER THE ORGANIZATION WILL ENTER INTO THE TRANSACTION. |
| FORM 990, PART VI, SECTION B, LINE 15 | COMPARABILITY DATA IS SUBMITTED ANNUALLY TO THE EXECUTIVE COMMITTEE FOR COMPENSATION APPROVAL FOR THE CEO AND ALL OTHER EMPLOYEES. |
| FORM 990, PART VI, SECTION C, LINE 19 | THE ORGANIZATION'S GOVERNING DOCUMENTS AND CONFLICT OF INTEREST POLICY ARE AVAILABLE UPON REQUEST. THE ORGANIZATION'S FINANCIAL STATEMENTS ARE AVAILABLE UPON REQUEST AND AT THE ORGANIZATION'S WEBSITE. |